Krause Fund Research

Fall 2025

Analysts

Joe Hotovec | *joseph-hotovec@uiowa.edu* Jenny Zhang | *jenny-zhang-1@uiowa.edu* November 17, 2025



Company: Pfizer, Inc. Sector: Healthcare Industry: Pharmaceuticals Exchange: NYSE (PFE)

Stock Rating: SELL

Target Price: 23.08 | Implied Return: -7.91%

Investment Thesis

We recommend a **SELL** rating for Pfizer with a target price of **\$23.08**, as shares trade above intrinsic value. The oncology pipeline and high dividend yield provide long-term support, and the recent acquisition of Metsera strengthens Pfizer's position in the GLP-1 obesity market. However, looming patent expirations, heavy capital requirements, and increased leverage continue to pressure returns.

Drivers

- ❖ <u>Upcoming drugs from Pfizer's pipeline:</u> Pfizer has 57 candidates in oncology, including 20 in Phase 3. Successful launches will help drive Pfizer's future performance and replenish lost revenues due to patent expirations.
- ★ <u>High dividend yield</u>: Pfizer offers a 6.86% yield, well above sector peers, and its capital allocation strategy supports steady growth with a modeled \$0.04 annual increase.
- ❖ Pfizer & Trump deal to lower U.S. drug prices: As part of the deal, Pfizer will be exempt from the pharmaceutical-specific tariff for the next three years. This deal reduces policy uncertainty and regulatory risk, providing more stability in Pfizer's outlook.


Risks

- ❖ Patent cliff: Several key Pfizer products face expirations over the next decade, with our model projecting an 80% sales decline in the year when patents expire as generics enter the market.
- ❖ Competitive landscape: GLP-1 drugs are the fastest-growing obesity treatments, but Pfizer has struggled to compete after halting several candidates over safety concerns. The company is now relying on acquisitions to gain entry, increasing leverage and raising its WACC to 6.28%.

Financial Overview				
Valuation Summary				
DCF/EP	23.08			
DDM	61.58			
P/E (2025)	26.54			
P/E (2026)	22.78			
Price Data				
Current Price*	\$25.06			
52 Week Range	\$20.91 - \$27.69			
YTD Return	-5.54%			
Beta	0.42			
WACC	6.28%			
Share Highlights				
Market Capitalization*	\$142.48B			
Shares Outstanding	5.69B			
Dividend Yield	6.86%			
Financial Ratios				
2024 Quick Ratio	0.74			
2024 Current Ratio	1.17			
2024 Profit Margin	12.67%			
2024 Debt-to-Equity	1.41			
2024 R&D as % of Sales 17.0%				
Source: FactSet [7], Team estimates				
*All prices as of close November 14, 2025				

Company Overview

Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company that discovers, develops, manufactures, and distributes medicines worldwide. It operates across developed and emerging markets to advance prevention, treatment, and cures for unmet medical needs. Founded in 1849 by Charles Pfizer Sr. and Charles Erhart, the company is headquartered in New York City [1].



Revenue Analysis & Decomposition

Pfizer's total revenues increased from \$59.6B in 2023 to \$63.6B in 2024, which is a 7% increase YoY [2]. This growth was primarily driven by acquisitions, portfolio growth, and significant non-cash adjustments related to COVID-19 products [2]. Pfizer's revenue consists of 4 main reported segments: Primary Care/Vaccines, Specialty Care, Oncology, and Pfizer CentreOne/Ignite.

Primary Care

Pfizer's Primary Care division is by far its largest with \$30.1B in revenue in 2024 [2] and includes a medicine portfolio of brands that treat cardiovascular issues, migraines, vaccines, and includes vaccines for COVID-19. Leading brands in this category include Eliquis, Nurtec, the Prevnar family, and Paxlovid. We forecast moderate, steady growth for this segment as COVID-related revenues normalize but remain recurring at a lower level. While key products will face patent expirations later in the decade, the overall primary-care market Pfizer serves is expected to maintain consistent demand, supporting our long-term 2% annual growth assumption.

Specialty Care

The Specialty Care segment generated \$16.7B in 2024 [2] and includes inflammation & immunology brands and biosimilars for chronic immune and inflammatory diseases. It also encompasses injectables used by Hospitals and treatments for rare diseases. Well-known medicines include Xeljanz, Enbrel, and the Vyndaqel family. We project steady mid-single-digit growth at 3% as rare-disease and biosimilar treatments maintain pricing power and expanding patient pools, driven in large part by the aging U.S. population. This rate exceeds Primary Care's 2% because Specialty Care therapies are more targeted, command higher pricing, and benefit from less competitive pressure.

Oncology


The Oncology portfolio brought in \$15.6B in 2024 [2] and includes ADVS, small molecules, bispecifics, and other immunotherapies that treat a wide range of cancers, including breast cancer, malignancies, and lung cancer. This segment includes brands such as Ibrance, Xtandi, and Padcev. We forecast Oncology to grow from \$15.6B in 2024 to over \$35B in 2040, driven by the aging population and rapid uptake of newer assets such as Padcev, Adcetris,

and Elrexfio. While legacy products decline over time, they are more than offset by expansion across ADC and bispecific pipeline. Growth of the area moderates to $\sim\!6\%$ as medicines mature.

CentreOne/Ignite

Pfizer CentreOne provides contract manufacturing and API supply services, while Ignite focuses on helping biotech partners scale their molecules. We assumed slow, stable growth for this segment as steady outsourcing trends support consistent, but limited expansion. Combined, the areas were responsible for \$1.2M of revenue in 2024.

Revenue by Segment in 2024



Source: Pfizer 10-K, p. 35-37 [2]

On an individual product level, Pfizer's revenues come from a few key products. In 2024, 11 products collectively accounted for 66% of total revenues [2]. A significant part of the revenue increase for 2024 reflects favorable non-cash adjustments related to COVID-19 products, which reversed prior inventory write-downs and making the YoY growth seem larger. The following chart provides a detailed revenue breakdown and significant concentration by several of Pfizer's major products. In this case, the "Other" category is the aggregation of numerous smaller products, each accounting for 2% or less of total revenue in 2024. As of November 2025, Pfizer's product list includes approximately 387 items [3].


Revenue by Product in 2024

Product	2024 Revenue	% of Total	Segment
	(in Billions)	Revenue	
Eliquis	7.37	12%	Primary Care
Prevnar family	6.41	10%	Primary Care
Paxlovid	5.72	9%	Primary Care
Vyndaqel family	5.45	9%	Specialty Care
Comirnaty	5.35	8%	Primary Care
Ibrance	4.37	7%	Oncology
Other	28.96	46%	-
Total	63.63		

Source: Pfizer 10-K, p. 35-37 [2]

Growth by Geographical Region

Revenue by Geography in 2024



Source: Pfizer 10-K, p. 101 [2]

According to Pfizer's revenues by geography, there is a clear geographical shift driven by declining international sales related to COVID-19 products between 2022 to 2024. As a result, Pfizer is increasingly reliant on its U.S. market,

which means that their financial performance may be more directly tied to the impacts of U.S. government regulation [2]. For example, in October of 2025, Pfizer and Trump reached an agreement to lower drug prices in the U.S., which may drive higher demand due to favorable pricing [4].

Drug Pipeline

Patent Expirations

Product	U.S. Patent Expiration	Europe Patent Expiration	Japan Patent Expiration
Eliquis	2026	2026	2026
Prevnar	2026	-	2029
Family			
Paxlovid	2041	2041	2041
Vyndaqel	2025 (2028	2026	2026/2029
Family	pending		
	PTE)		
Comirnaty	2041	-	2041
Ibrance	2027	2028	2028
Xtandi	2027	-	-
Padcev	2033	-	-
Nurtec	2030	2035	2030
ODT/Vydura			
Xelijanz	2026	2028	2025
Inlyta	2025	2025	2025
Abrysvo	2036	-	2036

Source: Pfizer 10-K, p. 7-8

Currently, several of Pfizer's top-selling products, including Eliquis, Prevnar, and Ibrance, are facing patent expirations in 2026 and 2027 [2]. This is a significant risk to revenues, as research indicates pharmaceuticals can lose about 80% of their product revenues within the first 20 weeks following patent expiration, with generic versions entering the market at up to 80% lower prices [5]. To address this wave of patent expiration, Pfizer will likely focus on new product launches, strategic acquisitions, and continued investment in its pipeline.

To capture the impact of patent expirations, we adjusted values in our revenue forecast by applying an 80% decline in sales in the year the U.S. patent expires. Based on this approach, we estimate that Pfizer has about \$25.97B of revenues at risk between 2026 and 2028 due to upcoming loss of exclusivity and the resulting competition.

Year	Forecasted Revenue Loss (in Billions)	Major Patent Expiring Products
2025	6.89	Vyndaqel family
2026	14.47	Eliquis, Prevnar family, Xeljanz, Inlyta
2027	3.92	Ibrance
2028	0.69	Enbrel
Total	25.97	-

Source: Team estimates

To address the projected revenue losses, Pfizer continues to invest in new product launches and strategic acquisitions. As of November 2025, Pfizer's pipeline includes approximately 101 product candidates in various stages [6]. Of its pipeline candidates, Pfizer has:

❖ Oncology: 57

Inflammation & Immunology: 24

❖ Internal Medicine: 10

Vaccines: 10

Currently, 30 candidates are in Phase 3, including 20 latestage candidates in oncology and several in inflammation & immunology [6]. This late-stage development will most likely help offset the upcoming patent expirations and bring new revenue streams to maintain market share. Some are listed below.

Phase 3 Theranies in Development

Phase 3 I herapies in Development				
Compound	Area of	Submission	FDA Status	
Name	Focus	Type		
Dazukibart	Inflammation & Immunology	New molecular entity	Orphan, Fast Track	
HYMPAVZI	Inflammation & Immunology	Product enhancement	Orphan, Fast Track	
IBRANCE	Oncology	Product enhancement	Breakthrough	
Ibuzatrelvir	Internal Medicine	New molecular entity	Fast Track	
Osivelotor	Inflammation & Immunology	New molecular entity	RPD, Fast Track, Orphan	
PF- 06760805	Vaccines	New molecular entity	Breakthrough, Fast Track	
PF- 07307405	Vaccines	New molecular entity	Fast Track	

Source: Company data [6]


Expedited FDA Designations for Pipeline Drugs

The FDA grants special designations for drug development intended to speed up the development and availability of treatments for serious conditions. These indications include Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review [26]. These designations mean that it is more likely for the product to be approved because they receive more guidance and support, therefore reducing development risk [34].

Expense Analysis

Pfizer has a profit margin of 12.6%, which means that its expenses make up 87.4% of its revenue [2]. Unsurprisingly, Cost of Sales and Selling, General & Administrative expenses are the two largest items. It is important to note that Pfizer's R&D accounts for 17% of revenue, which is below the industry average of 21% [7]. This is an unfavorable sign given that differentiation in the pharmaceutical industry is driven by a company's investment in R&D to achieve breakthroughs that result in new drugs and treatments.

Items as % of Sales



Source: Pfizer 10-K, p. 37 [2]

Cost of Sales

Cost of Sales decreased \$7.1B in 2024, primarily due to the non-recurrence of a non-cash charge of \$6.2B in 2023 related to Paxlovid and Comirnaty recorded for inventory write-offs and a favorable change in sales mix driven by lower sales of Comirnaty [2].

Cost of Sales has historically been Pfizer's largest expense since 2021, representing 28.1% of sales in 2024 [2]. We forecast that this pattern will continue going forward because Pfizer's product mix is expected to remain weighted toward therapeutics and vaccines with relatively high manufacturing and distribution costs. Furthermore, the company is unlikely to return to the extreme margins it saw during peak COVID-19 years.

Selling, General & Administrative


Selling, General & Administrative expenses decreased \$41M, mostly due to a \$790M decrease in promotional and marketing expenditures for COVID-19 products. This decrease was partially offset by higher compensation-related expenses and corporate functions driven by the Seagen acquisition [2].

Looking ahead, we expect SG&A to remain roughly in line with its 10-year average as a percentage of sales (25.0%), as Pfizer continues its normal commercial spending following the winddown of COVID-19 product support. Pfizer's mature product portfolio, global footprint, and consistent investment limit drivers that would greatly change SG&A.

Research & Development


Research & Development expenses increased \$143M, primarily due to a net increase in spending of \$1.1B mainly to develop certain product candidates acquired from Seagen, and an increase of \$680M in compensation-related expenses [2].

R&D costs are necessary for pharmaceutical companies like Pfizer to survive and replace losses which occur when products lose exclusivity or market share. These new product lines are primarily driven through internal R&D, collaborations, acquisitions, joint ventures, or licensing agreements.



Source: FactSet [7]

Although R&D spending is essential for delivering breakthroughs and critical for survival, Pfizer has historically spent less than its competitors (17% of revenue in 2024, compared to an estimated peer average of 21%). This is a trend that we forecast to continue, with Pfizer spending 17% of its sales on R&D. This is flatlined from 2024 because before COVID-19, spending floated around 14% with a jump up to 20% in 2020. Post-COVID, spending remained elevated with 18% and 17% on R&D in 2023 and 2024 [2]. In line with historical data over the past five years, we project Acquired In-Process R&D to make up 1.5% of sales. This is supported by Pfizer's continued aggressive approach to acquiring smaller companies like Metsera, who it recently outbid Novo Nordisk to acquire [33].



Source: FactSet [7]

Cost Management

In October 2023, Pfizer launched its cost realignment program, which began in response to anticipated revenue declines from COVID-19 products [40]. Initially, management initially targeted \$3.5B in cost cuts through 2024. Most of the cuts were from R&D spending, but layoffs and select facility closures were affected as well [41]. Over time, Pfizer has been gradually increasing their targeted cost cuts as the company reaches its goals. In the Q3 2025 earnings call, Pfizer expects to save \$4.5B by the end of 2025 [42]. Pfizer has also increased their cost reduction target to \$7.7B though 2027 [42].

In addition to these cost reductions, Pfizer's management has publicly expressed support for the dividend and part of their capital allocation strategy includes maintaining and growing the dividend over time [42]. Although Pfizer has significantly cut R&D spending, Pfizer also hopes that these savings will be reinvested into the pipeline as well [42]. In our valuation model, we plan to take these cost reduction initiatives into consideration through further adjustments to Cost of Sales, SG&A, and R&D expenses.


Earnings

On the most recent earnings announcement, Pfizer reported Q3 2025 results. Q3 revenues declined 6% YoY primarily driven by continuing decline in COVID-19 products and a one-time in-process R&D expense related to Pfizer's licensing deal with 3SBio [21, 43]. This licensed asset is expected to be a foundational component for Pfizer's long-term Oncology portfolio and will help offset the impact of declining revenues. Operating expenses remain controlled: SG&A is stable as Pfizer integrates Seagen, and R&D spending is targeted toward high-return programs. Pfizer's acquisition of GLP-1 developer Metsera will also help to capitalize on health care trends and further boost profitability [8].

Given the current development, management raised and narrowed full-year 2025 EPS guidance while reaffirming revenue guidance due to strong revenue growth from recent launches and acquired products [8]. This signals that the company is confident in the business and its progress with ongoing cost improvement initiatives.

Looking ahead, Pfizer's earnings performance over the forecast period is driven by shifts in product mix, the timing

of loss-of-exclusivity events, and the normalization of COVID-19 revenues. These dynamics support our EPS estimates, which exceed consensus, reflecting the company's ability to maintain profitability through margin expansion, portfolio growth, and efficient cost management.



Source: FactSet [7], Team Estimates

Our EPS estimates differ meaningfully from consensus because we forecast reported EPS, while most analysts publish adjusted EPS, which excludes restructuring charges, amortization of intangibles, and other non-cash or one-time items. These adjustments inflate the earnings number, resulting in consensus figures above \$3.00 in the near term even as reported earnings remain lower [37]. By contrast, our estimates show a lower starting point but a clearer underlying trend. Presenting both sets of numbers allows us to highlight the gap between Street expectations and reported results. The differences also show why focusing on reported EPS provides a more realistic view of Pfizer's overall performance.

Pfizer's reported EPS demonstrates a clear trend of moderate long-term growth. After peaking in 2021–2022 due to elevated COVID-related revenues, reported EPS declined sharply in 2023–2024 as non-recurring gains reversed and inventory write-downs stabilized. Our projections show steady growth from \$1.40 in 2025 to \$2.69 in 2029, reflecting consistent revenue expansion in primary- and specialty-care segments and margin stabilization, which is talked about later. Consensus EPS, in contrast, starts higher but declines over. This comparison highlights the importance of considering both reported and adjusted figures to capture Pfizer's sustainable earnings power and long-term growth trajectory.

Capital Structure

In 2024, Pfizer's debt-to-equity was 1.41, as calculated by Total Liabilities/Total Equity. This falls at the midpoint of the historic range over recent years from 1.06-1.87. Its historical low of 1.06 was hit in 2022, likely due to high earnings, which increased retained earnings. Pfizer's long-term debt is rated high-quality by both Moody's (A2) and S&P (A) [7], which falls in the upper medium grade of its ratings. However, in 2023, both downgraded Pfizer's rating due to the high debt used to finance the Seagen acquisition [1]. Despite this, the high-quality rating indicates that Pfizer has a strong ability to meet its debt obligations, though it is more sensitive to economic conditions than higher rated companies. Pfizer sits within its peer group who have similar debt ratings with Johnson & Johnson at AAA, Merck & Co. at A, and Gilead Sciences at A-.

Debt Schedule

Debt Schedule		
Debt Maturity	Long Term Debt	Weighted Average
		Interest Rate
2025	-	-
2026	6.00B	3.7%
2027	0.98B	2.2%
2028	5.66B	4.6%
2029	1.75B	3.5%
2030	5.25B	3.6%

Source: Pfizer 10-K, p. 78 [2]

Compliance Costs Related to Environmental Expenditures Pfizer's operations are affected by national, state, and local environmental laws, and management intends to continue to make the expenditures needed for compliance [2]. While environmental contamination clean-up from past industrial activity is an ongoing process and difficult to estimate with certainty, management expects these environmental costs to be immaterial as of 2024 [2]. However, Pfizer is working toward achieving the SBTi Corporate Net-Zero Standard by 2040, a goal that is expected to incur incremental capital and operational expenditures in the longer term [2].

Investment Costs Related to Capital Expenditures


For companies in the pharmaceutical industry, capital expenditures are purchases of long-term assets that mainly support R&D and drug manufacturing. This is inclusive of labs, specialized testing facilities, and plants to manufacture active ingredients. In 2024, Pfizer spent \$2.9B on purchases of Property, Plant and Equipment, which is down from

\$3.9B in 2023 and \$3.2B in 2022 [2]. The elevated CapEx reported in 2023 was largely driven by COVID-related production and acquisition integration [2]. Management predicts that Pfizer's amount of debt could have significant consequences, including reducing the cash flow available to fund capital expenditures. In the forecast, the CapEx amount is kept consistent, reflecting current operational needs, including ongoing maintenance, efficiency upgrades, and support for pipeline drugs.

Investment Costs Related to Acquisitions

Management expects to have additional expenditures related to acquisition activity in the future. This is reflected in our model with large expenditures in financing in the upcoming years as Pfizer works to pay off this debt.

Pfizer's Payout Policy and Shareholder Returns



Source: Pfizer 10-K, FactSet [7], Company data [9]

Pfizer has historically maintained a consistent dividend policy, regularly paying dividends even in years when the payout exceeded reported earnings. As of Q3 2025, Pfizer has paid 347 consecutive quarterly dividends [38]. This commitment shows the company's focus on returning value to shareholders. YTD, \$7.3B was returned to shareholders through cash dividends [43]. As of November 2025, Pfizer's dividend yield stands at a commanding 6.68% [7], reflecting both its high payout and strong confidence in its ability to sustain distributions. As a result, we have made sure to continue this trend of small, consistent dividend increases in our forecast.

S.W.O.T. Analysis

Strengths

Large Workforce: Pfizer has ~81,000 employees [10], which is on the higher range compared to its competitors [7]. This suggests strong retention and the ability to attract the specialized talent needed for drug development. A workforce of this scale allows Pfizer to support multiple research programs, manufacturing sites, and global efforts at one, ensuring a full pipeline. A large, stable workforce also supports operational consistency, which reinforces the revenue and margin assumptions used in our model.

Highly Successful Brand & Recognition: Pfizer is one of the largest pharmaceutical companies in the U.S. and has a strong presence across the globe; they operate in over 200 developed and emerging countries [10]. This global footprint allows the company to capture many revenue streams, reducing reliance on any single global region. From a modeling perspective, the brand strength supports stable baseline sales and lower volatility in international segments.

<u>R&D</u>: Currently, Pfizer's pipeline includes 101 products in development [6]. Pfizer's significant investment will help drive breakthrough therapies and innovation. A pipeline of this size increases the likelihood of future regulatory approvals and replenishes revenue lost from patent expiration. In the model, Pfizer's future products from its pipeline are included in each revenue segment to represent its future developments.

Revenue Growth/Trend: Pfizer has historically maintained strong market share and steady revenue generation. While volatility does exist, the company still benefits from durable legacy products and its global scale. This provides a stable foundation for revenue projections and reduces downside risk.

<u>Diversified Product Portfolio:</u> Some of Pfizer's therapeutic areas include oncology, vaccines, inflammation & immunology, internal medicine, rare diseases, and anti-infectives. This broad portfolio helps minimize concentration risk and smooths earnings when individual categories face competitive or regulatory pressures.

Weaknesses

<u>Reliance on Key Products:</u> Despite having a wide portfolio, a large share of revenue still comes from a few flagship products. This creates vulnerability when those products face new competition or pricing pressure. In forecasting terms, it increases revenue sensitivity and requires conservative assumptions for long-term growth.

Patent Expirations: Pfizer faces several upcoming patent cliffs, which typically result in rapid market share losses to generic or biosimilar manufacturers. These expirations have historically led to notable declines in revenue for major pharmaceutical players [5]. In our forecast, we applied an 80% first-year decline in sales after patent expiration to show the drastic effects of competition from generic brands.

Legal Issues and Brand Image: Pfizer has been accused and involved in multiple scandals involving false claims about drug effectiveness, data integrity issues, ethical issues, illegal marketing in off-label drugs, medical damage caused by its drugs, a tax dodging scheme, and other possible cases of fraud [11]. Of course, this is not an exhaustive list, but these controversies highlight a recurring pattern of potential legal and ethical issues. These problems have led Pfizer to pay severe penalties imposed by the SEC and other regulators and have negatively impacted Pfizer's reputation due to the information regarding their fines are public. As a result, this raises some concerns regarding Pfizer among investors, regulators, and the public.

Opportunities

Oncology Market: The oncology segment is expanding rapidly due to demographic shifts and advancements in targeted therapies [12]. Pfizer is well-positioned to capture this growth through both internal development and recent acquisitions. In the model, oncology provides a key driver for mid- and long-term revenue expansion.

M&A: Recent acquisitions such as Seagen and Metsera provide access to innovative platforms and broaden Pfizer's pipeline. These deals can accelerate revenue growth by reducing development timelines and increasing highmargin product opportunities. In financial modeling, M&A strengthens long-term projections and diversifies risk.

reduce R&D timelines and increase the probability of pharmaceuticals. technical success. This contributes to better margin expectations and more favorable R&D efficiency Phases of Clinical Trial assumptions in the model.

Government Incentives: In January 1983, the Orphan Drug Act (ODA) was introduced in the U.S. to encourage pharmaceutical companies to develop drugs for rare conditions by providing additional incentives when the expected sales would not justify the development costs. The U.S. government also grants tax credits on R&D costs and subsidies for Phase 1 to Phase 3 clinical trials [14].

Threats

Intense Competition: The pharmaceutical industry faces continual competition from branded drugs, generics, and biosimilars [12]. These competitors can quickly capture market share, especially after patent expirations. In our model, this competitive pressure requires conservative pricing assumptions and gradual erosion of mature product revenues.

U.S. Government Regulation: Pfizer is heavily exposed to FDA oversight, and delays or failures in clinical trials can materially impact projected revenue streams. Upcoming regulatory and pricing reforms also create uncertainty for future profitability. In the model, this introduces scenario risk and widens the range of potential outcomes.

High Capital Requirements: Pharmaceutical R&D and manufacturing demand significant upfront investment with long payback periods [12]. This places ongoing pressure on cash flow and increases sensitivity to development setbacks. In modeling terms, high capital intensity elevates required returns and impacts free cash flow during investment-heavy years.

Industry Analysis

Industry Overview

The pharmaceutical industry refers to companies that develop, market, and sell drugs made from molecules that are chemically synthesized. These companies are required to go through the drug development cycle and are heavily

AI: AI is increasingly used to improve drug discovery, regulated by the FDA. A company's portfolio, pipeline, and streamline clinical trial design, and enhance operational processes of pre-clinical and clinical trials are important efficiency [13]. Pfizer's adoption of AI can materially factors in making decisions related to investing in

Development	Description	Pfizer's
Phase		Pipeline
Phase 1	Trials on drugs' safety	37
Phase 2	Trials on drugs' effectiveness	30
Phase 3	Trials on dosage and larger samples	30
Registration	Regulatory review for approval	4

Source: Company data [6]

Within this pipeline, novel drugs, defined as new molecular entities (NMEs) or new biologics, are therapies that have never been approved or marketed in the U.S. [18]. This is important in the pharmaceutical industry because they help drive further growth and differentiation.

FDA Novel Drug Therapy Approvals

I Dilitorel Diag	nerupy ripprovuis	
Year	Total Approvals	Pfizer Approvals
2025	36	0
2024	50	1
2023	55	5
2022	37	1
2021	50	1

Source: FDA [18], Company data [6]

Historically, there is a lot of uncertainty across the pharmaceutical industry. Only 10% of Phase 1 candidates will make it to approval. Moreover, the process takes, on average, 10 years to move from Phase 1 to regulatory approval [35]. While the number of FDA approvals has remained relatively consistent, studies show that FDA standards for novel drug approvals have become more relaxed in recent years [36]. As a result, there are more treatment options for life threatening conditions but with less evidence that they are safe and effective. The FDA handles these risks through special designations [18].

Pharmaceutical Industry Operations and Product Lines

Pharmaceutical companies operate across a diverse range of product lines, including innovative and generic pharmaceuticals, biologics, biosimilars, and over-thecounter (OTC) drugs. Firms typically have segments such as contract research services, manufacturing, packing & management consulting, labeling, contract

therapy, prescriptions, and OTC medicines.

Firms differentiate themselves through patent filings and market exclusivity, which ultimately means firms that manufacture branded versus generic drugs. They also differentiate based on the perceived quality through price, R&D investments, pipeline assets, and marketing.

Recent Developments & Trends

Anti-obesity drugs dominate the spotlight

As the popularity of anti-obesity drugs continues to skyrocket [15], attracting many new companies to compete with the current leaders Novo Nordisk and Eli Lilly. The market for these drugs is projected to be immense, with estimates projecting a \$362B market size and GLP-1 therapies capturing 9.0% of global drug sales by 2030 [12]. The data on clinical trials for convenient and non-invasive alternatives to current GLP-1 therapies are highly anticipated and will likely play an important role in investors' decisions.

U.S. Policy risks under the Trump Administration

One of the biggest risks in the pharmaceutical industry is changing policy under the new Trump administration. For instance, in November 2024, when Robert F. Kennedy Jr. was nominated to lead the U.S. Department of Health, pharmaceutical stocks fell sharply [16]. However, Trump's recent agreement with Pfizer mitigates some of this risk. Under this deal, Pfizer has committed to sell many of its drugs to Medicaid at "most-favored-nation" prices, matching the lowest paid in other developed countries [4]. These discounts on Pfizer's primary-care and specialty medicines will range as high as 85% (with an average of 50%) through the TrumpRx platform [42]. In return, Pfizer receives a three-year waiver from pharmaceutical-specific tariffs [17]. This deal will provide Pfizer with a more stable pricing framework going forward and limit exposure to tariffs.

While these direct pricing agreements may affect Pfizer's revenues, broader federal spending could reduce demand and slower price growth throughout the pharmaceutical sector. For example, a significant risk comes from the passage of the One Big Beautiful Bill Act, enacted in July 2025, which cuts \$1.1T in federal health spending over the next decade, and is projected to remove health coverage from roughly 15 million people beginning in 2027 [29].


wholesaling. Revenue is generated through streams like While historical Medicaid cuts have often been offset by subsidies or private market competition, this policy shift positions the sector for slightly weaker revenue expansion relative to recent years.

Catalysts for Growth

Drug Approvals by FDA & EMA

The FDA approved 50 novel drugs in 2024, contributing to a 22% increase over 2015-2019 levels [18, 12], while the EMA recommended 114 medicines for marketing authorization [19, 12]. Forecasts from IQVIA, a leading global provider of clinical research and insights, anticipate continued momentum, with an average of 55 annual launches in the U.S. and 40 in Europe over the next three years [20]. Higher approval volumes increase the overall probability of pipeline monetization for major firms, which supports stronger long-term revenue projections and reduces uncertainty in our model's later-stage cash flows.

Drug Approvals by FDA & EMA



*EMA data for 2025 is not yet available.

Source: S&P NetAdvantage [12]

Worldwide Prescription Drug Sales Growth


Global prescription drug sales are expected to grow at a CAGR of 6.3%, reaching roughly \$2.0T by 2032 [12]. This industry expansion is driven by sustained demand in chronic disease, oncology, and immunology, which are areas where large-cap pharmaceutical firms have strong competitive positions. For the model, this provides the foundation for higher revenue growth assumptions, particularly for firms with diversified portfolios and wellpositioned market share.

AI Adoption Across R&D and Operations

AI integration is rapidly improving drug discovery efficiency, clinical trial design, and manufacturing precision [12]. These advancements lower development

costs, accelerate timelines, and increase the probability of face extreme pricing competition when they lose technical success. In the model, AI contributes to improved margin structure (through lower R&D and operational costs) and supports more favorable long-term returns on invested capital.

Porter's Five Forces



Source: S&P NetAdvantage [12]

Threat of New Entrants: Low

The pharmaceutical industry has high barriers to entry due to the significant investments needed for a company to establish R&D, manufacturing, marketing, and distribution. Additionally, if a company fails to produce viable drugs in time, it will not be able to generate profits. Given that the discovery and development process is time-consuming, costly, unpredictable, and subject to strict regulation, these further deter investors from entering pharmaceutical industry.

Threat of Substitutes: Moderate

When a company develops a new drug and receives regulatory approval, the company gains patent protection and market exclusivity for 10-20 years, during which the drug has essentially no substitutes. However, once the patent expires, generic production begins immediately, and the number of substitutes rapidly enter the market, leading to a substantial loss of revenue. Generic drugs provide an identical active ingredient and are priced at a substantial discount, often 80% to 85% lower than the branded drug [12]. Biosimilars, the biologically equivalent versions of the drug, are typically priced at a 30% discount [12].

Bargaining Power of Buyers: Moderate

Pharmaceutical companies have a high ability to control drug prices for branded products while patented but will exclusivity. The rise in the number of producers increases customers' bargaining power. Also, large customers like hospital networks negotiating on behalf of big health insurers often command much greater bargaining powers compared to individuals.

Bargaining Power of Sellers: Low

Drug manufacturers require raw materials, manufacturing equipment, and packaging materials from suppliers. The rest of the expenses usually relate to R&D and internal efforts. Production materials are basic and available from many suppliers, which means suppliers have limited power to influence prices.

Degree of Rivalry: High

Low product differentiation and low switching cost lead to extreme rivalry in the pharmaceutical industry. There are also many participants in the industry whose branded drugs compete to treat similar conditions, even if their approach is different. Patent expiration leads to the production of generics, which further fuels competition.

Pharmaceutical Competition

To select comparable peers for Pfizer, we focused on largecap U.S. pharmaceutical companies with diversified products and pipelines. In our analysis, we focused on Pfizer's closest competitors from branded pharmaceuticals.

Ticker	Company Name
AMGN	Amgen
BMY	Bristol Myers Squibb Co
GILD	Gilead Sciences Inc
GSK	GSK PLC
JNJ	Johnson & Johnson
LLY	Eli Lilly & Co
MRK	Merck & Co
VRTX	Vertex Pharmaceuticals Inc

The pharmaceuticals industry was the second-largest industry in the global health care sector in 2024 [12]. Johnson & Johnson was the biggest individual revenue contributor to the industry and generated 10.8% of the industry revenue [7, 12]; however, they are not purely a pharmaceutical company, as its core business is split into the Innovative Medicine and MedTech segments as well. Novo Nordisk, best known for its presence in the insulin and obesity markets, leads in terms of operating margin. We did not include Novo Nordisk in our peer analysis because Leverage/Liquidity Comparison they are based in Denmark and their financial statements do not use GAAP.

Profitability Comparison

Company	Gross Margin	Net Margin	FCF Margin
PFE	65.77%	12.60%	15.46%
AMGN	64.19%	12.31%	31.28%
BMY	56.80%	-18.53%	28.87%
GILD	78.24%	1.67%	35.87%
GSK	69.80%	8.21%	14.95%
JNJ	68.63%	15.84%	22.34%
LLY	81.31%	23.51%	8.35%
MRK	73.74%	26.76%	28.29%
VRTX	86.07%	-4.88%	-7.19%
Average	71.62%	8.61%	19.80%

Source: FactSet [7]

Pfizer's profitability metrics show performance above the industry average net margin but slightly below average gross margin and free cash flow margin. Overall, Pfizer demonstrates stable profitability, with strength in net margin driven by cost management, but opportunities remain to optimize cash generation.

Gross Margin: at 65.77%, Pfizer is slightly below the peer average of 71.62%, indicating moderate but relatively weaker control over production and COGS compared to other large pharmaceutical firms.

Net Margin: at 12.60%, Pfizer is above the peer average of 8.61%, suggesting solid profitability after operating expenses and taxes, though it lags behind leaders like Merck and Eli Lilly. This performance is most likely driven by Pfizer's enterprise-wide cost realignment program [41].

Free Cash Flow Margin: at 15.46%, Pfizer is below the peer average of 19.80%, highlighting room for improvement in converting revenue into cash, especially relative to companies like Amgen and Gilead.

Company	Debt-to- Equity	Debt Rating	Current Ratio	Quick Ratio
PFE	0.76	A	1.17	0.92
AMGN	Outlier	BBB+	1.26	0.95
BMY	3.13	A	1.25	1.15
GILD	1.41	A-	1.6	1.45
GSK	1.24	A	0.78	0.52
JNJ	0.53	AAA	1.11	0.86
LLY	2.37	A+	1.15	0.89
MRK	0.83	A+	1.36	1.15
VRTX	0.11	-	2.69	2.35
Average	1.30	-	1.37	1.14

Source: FactSet [7]

Pfizer's leverage and liquidity profile shows a moderate level of debt and adequate short-term liquidity compared to its peers. Compared with highly leveraged peers like Bristol Myers Squibb or Eli Lilly, Pfizer appears more conservative in financing, though it is less liquid than companies like Vertex or Gilead. Overall, Pfizer balances manageable leverage with adequate liquidity, positioning it for operational stability while maintaining flexibility for strategic investments.

Debt-to-Equity Ratio: at 0.76, Pfizer is well below the peer average of 1.30, indicating that Pfizer uses less leverage than many large pharmaceutical companies, which may provide financial flexibility and lower interest obligations.

Current Ratio: at 1.17, Pfizer is slightly below the peer average of 1.37, suggesting Pfizer has sufficient but not excessive short-term assets to cover its liabilities.

Quick Ratio: at 0.92, Pfizer is slightly below the peer average of 1.14, confirming that Pfizer's short-term assets are generally sufficient to cover short-term debt.

Efficiency Comparison

	Asset	Inventory	Receivables
Company	Turnover	Turnover	Turnover
PFE	0.29	2.07	6.96
AMGN	0.35	1.44	4.85
BMY	0.51	8	4.74
GILD	0.47	3.58	6.29
GSK	0.54	1.72	4.32
JNJ	0.51	2.36	5.88
LLY	0.63	1.26	3.96
MRK	0.57	2.7	6.40
VRTX	0.48	1.57	6.75
Average	0.48	2.74	5.57

Source: FactSet [7]

Pfizer's efficiency metrics suggest it operates with lower turnover compared to the pharmaceutical peer group. Overall, Pfizer's lower asset turnover is largely due to high levels of goodwill and intangible assets from M&A activity, which do not generate revenue immediately. However, this is partially offset by efficient cash collection, resulting in strong receivables turnover.

Asset Turnover: at 0.29, Pfizer is below the peer average of 0.48, indicating that Pfizer generates less revenue per dollar of assets than most competitors, and therefore less efficient. A majority of Pfizer's total assets consist of intangible assets and goodwill. These intangible assets are derived heavily from debt-financed acquisitions and are not expected to generate revenue in the short term, resulting in a weak turnover ratio.

<u>Inventory Turnover:</u> at 2.07, Pfizer is below the peer average of 2.74, suggesting slower movement of inventory relative to peers. However, this is expected due to long lead times in the pharmaceutical industry. Compared with companies like Bristol Myers Squibb or Gilead, which show high inventory and asset turnover, Pfizer appears more asset- and inventory-heavy, which may reflect larger-scale operations or longer product cycles. While this conservatism can provide stability, it may also point to opportunities for improving operational efficiency.

Receivables Turnover: at 6.96, Pfizer is above the peer average of 5.57, showing that the company can efficiently and reliably collect from customers. This is important because pricing and reimbursement for Pfizer's products depend on government programs, such as Medicare and Medicaid. These programs, along with negotiated contracts, can result in significant delays due to chargebacks, rebates,

sales allowances and sales returns which can take up to one year to settle [2].

Products by Development Phase

Company	Phase 1	Phase 2	Phase 3	Registration
PFE	37	30	30	4
AMGN	22	15	6	1
BMY	28	27	14	-
GILD	12	14	5	-
GSK	21	38	10	8
JNJ	13	22	11	6
LLY	28	34	11	4
MRK	16	22	17	3
VRTX	3	10	2	-
Average	20	23.56	11.78	2.89

Source: FactSet [7]

This table highlights the meaningful differences in major pharmaceutical companies' pipeline across Phases 1, 2, and 3. Pfizer leads early-stage development with 37 Phase 1 programs, signaling a strong foundation for long-term innovation. Merck & Co and Bristol-Meyers Squibb show heavier concentrations in later phases, which mean a higher likelihood of approvals. Other companies have smaller pipelines, indicating limited future product flow through internal development.


Pfizer sits in a stable position within the large-cap pharmaceutical landscape, though its performance varies across segments. The company's profitability aligns with peers, with net margins above the group average. Pfizer maintains a stronger balance sheet with lower leverage, but slightly tighter liquidity ratios. Efficiency metrics, such as asset and inventory turnover, fall behind those of competitors. Despite these metrics, Pfizer's full and diverse pipeline provides meaningful growth potential relative to its competitors.

Economic Analysis


Aging Population

For the past 50 years, global average life expectancy has been significantly rising due to massive improvements in infant and child mortality rates, improved living standards, better nutrition and sanitation, and advances in health care (such as successes in antibiotics, vaccines, and breakthrough drugs such as insulin) [23]. As the average lifespan increases, this results in the demographic shift towards a larger elderly population as well as the prevalence


of chronic conditions, leading to a growing demand for Rising Obesity Rates pharmaceutical consumption and health care services.



The U.S. life expectancy follows the same long-term upward trend. Although it declined temporarily during the COVID-19 pandemic (2019-2021), it has since rebounded and continues to increase [39]. The following U.S. population pyramids further illustrate the shift, as the proportion of Americans aged 65 and older grew from 12.19% to 16.07% from 2000 to 2020 [22].



We forecast that average life expectancy will continue to steadily increase for a while towards the maximum lifespan. However, the average life expectancy will most likely not change in a very dramatic way in the next 2-3 years. In our view, the projected increase in the elderly population will put increasing pressure on the health care system, as people aged 65+ spend the most on health care with a disproportionately greater use of prescription drugs [12].



Source: Statista [24]

Recent data shows that U.S. obesity rates have declined slightly for the first time in more than a decade, falling from 41.9% in 2017-2020 to 40.3% in 2021-2023. Although direct data on GLP-1 drug usage is limited, the timing of this shift aligns closely with the rapid rise of GLP-1 medications such as Ozempic and Wegovy [15], both of which reached blockbuster status over the same period. These drugs, originally developed for diabetes, have become increasingly mainstream for weight loss and cardiovascular benefits, making GLP-1 receptor agonists fastest-growing therapeutic category the pharmaceutical industry [25].

This expansion has not occurred without friction. Despite their clinical effectiveness, GLP-1 drugs face cost scrutiny, supply constraints, and uneven insurance coverage, particularly within Medicare and Medicaid, where recent policy proposals and reversals highlight how political and regulatory forces shape access to treatment. Public criticism from figures such as HHS Secretary Robert F. Kennedy Jr., who argues that obesity should be addressed through lifestyle changes rather than medication [27], further underscores the uncertainty surrounding long-term reimbursement and adoption trends.


Looking forward, we expect obesity rates to continue declining as GLP-1 drugs move further into mainstream use, though affordability and policy risk remain significant headwinds. For our model, this means we can assume obesity rates will slowly decline and demand for GLP-1 treatments will stay steady, but we still need to account for policy and reimbursement risks by choosing more inflation [12]. Furthermore, the IRA allows the U.S. conservative growth rates.

Department of Health and Human Services (HHS) to

Inflation Trends (CPI)

The pharmaceutical industry is affected by inflation, which impacts costs and pricing. The sector's profitability benefits from the fact that medical care demand is relatively inelastic. Consequently, rising medical prices typically translate into higher revenues for health care companies.

Medical Care CPI & Overall CPI



Source: FRED [28]

The Consumer Price Index for Medical Care (CPIMEDSL) measures the price inflation consumers face for healthcare products and services. Recent data from the Federal Reserve shows that the Medical Care CPI increased 2.69% YoY in 2024 [28]. Historically, Medical Care CPI generally increased at a higher rate than Overall CPI for most of 1980-2020. Across the 65 years presented, Medical Care CPI has never experienced a negative full-year decline. The lowest annual increase was 0.50% in 2023.


However, when medical costs consistently increase faster than the overall inflation, it highlights the long-term unaffordability of health care services. Due to this, Medical Care CPI serves as a key indicator for policymakers assessing national health care affordability. Sustained periods of strong price growth can draw regulatory scrutiny, which may lead to reforms that directly affect profitability across the sector.

Looking ahead, this enduring growth pattern may face significant legislative risks that could influence the outlook on long-term pricing. For example, the Inflation Reduction Act (IRA), signed into law in August 2022, includes provisions that impose rebates if drug prices rise faster than

Inflation [12]. Furthermore, the IRA allows the U.S. Department of Health and Human Services (HHS) to negotiate prices for certain high expenditure Medicare covered drugs, a process known as Medicare Drug Price Negotiation Program (MDPNP) [12, 44]. For our model, this reinforces a cautious outlook on long-term medical price growth and supports the more conservative revenue assumptions embedded in our forecast.

Increase in U.S. R&D Trends

U.S. R&D Spending (as % of GDP)



Source: World Bank [30]

According to World Bank indicators, U.S. research and development (R&D) expenditure reached 3.59% of GDP in 2022 [30], reflecting the country's continued pattern of annual increases and prioritization of scientific and technological innovation. In the health care sector specifically, R&D serves as the foundation for developing new therapies, advancing medical technology, and addressing unmet clinical needs. Sustained investment in basic, applied, and experimental research is critical for maintaining the pipeline of future drugs and treatments, supporting long-term industry growth.

Given decades of consistent increases in U.S. R&D funding, we expect this trend to continue both in the near term and over the long horizon. Rising investment should support additional breakthroughs, expand therapeutic pipelines, and strengthen the competitive positioning of major health care companies. For our model, this expectation of continued R&D growth reinforces the long-term innovation assumptions embedded in Pfizer's forecast, particularly with respect to future NOPLAT expansion, new product introductions, and stable terminal value growth.

Valuation Analysis

Our estimate for Pfizer's share price is \$23.08. To determine the value of Pfizer stock, we used the following models: Discounted Cash Flow (DCF) and Economic Profit (EP), Dividend Discount Model (DDM), and Relative Valuation. Our forecasts are based on historical data (2014-2024) as reported on Pfizer's 10-K and were the foundation of our model and used in tandem with current industry and economic trends to project the company's financials through 2034E. Expiring patents and new drugs in the pipeline were also put into consideration. Our valuation models provide a forecast for the complete financial years 2025E-2034E, which captures the full lifecycle of pharmaceutical companies, including long R&D periods and patent exclusivity.

DCF and EP Model

Estimated Share Price: \$23.08 Implied Return: -7.91%

The DCF model determines the Value of Operating Assets by projecting and discounting the Free Cash Flow (FCF) for each year of the forecast horizon. The FCF is defined as the cash flow generated by operations after accounting for reinvestment in the business.

❖ FCF = NOPLAT-Change in Invested Capital

The EP model calculates the company's value creation above its cost of capital.

❖ EP = Beginning Invested Capital*(ROIC-WACC)

Both the DCF and EP models calculate a terminal value based on 2034's expected NOPLAT, representing the discounted value of all Pfizer's cash flows from the end of the 10-year forecast horizon and into perpetuity. This terminal value is discounted back to the present, using Pfizer's WACC of 6.28%.

After the discount is complete, non-operating assets are added, and non-operating liabilities are subtracted from the present value to arrive at a total equity value. As a result, we made the following non-operating adjustments:

- Plus: Excess Cash, Short-Term investments, Equitymethod investments, Long-Term investments
- Less: Short-Term Borrowings, Long-Term Debt, Pension and postretirement benefit obligations, Noncurrent deferred tax liabilities, Other taxes

payable, Other noncurrent liabilities, Equity attributable to noncontrolling interests

When the value of the equity is divided by the number of shares outstanding, the implied share price is calculated. It is important to remember to adjust this share price forward in time to the present day (87.40% as of November 15).

We believe the DCF/EP model provides a reliable estimate of Pfizer's intrinsic value. It accounts for the company's future cash flows, capital expenditures, and cost of capital, which captures the effect of Pfizer's investments in R&D and pipeline development. By incorporating a terminal value, the model reflects long-term growth potential beyond the 10-year forecast. Additionally, the EP adjustment highlights return relative to the company's invested capital, providing insight into value creation. Overall, we view this as the most grounded measure because it directly considers operational and strategic realities rather than relying solely on market multiples.

Dividend Discount Model (DDM)

Estimated Share Price: \$61.58 Implied Return: 145.72%

The DDM, like the DCF/EP method, discounts future cash flows and the terminal value back using a discount rate to arrive at the present value. In this case, the cash flows discounted are the estimated dividend payments. The terminal value is calculated by using the terminal P/E ratio and then multiplying it by the terminal year's EPS. This future stock price is then discounted along with the dividend payments using the cost of equity, not the WACC. Unlike the DCF/EP model, no adjustments regarding non-operating assets and liabilities are made after this point.

We do not believe the DDM provides an accurate valuation for Pfizer. This model focuses solely on projected dividend payments and discounts using the cost of equity, ignoring the company's substantial capital expenditures, R&D investments, and changes in working capital. As a result, it overstates the company's value, producing an implied share price that is significantly higher than both the DCF and market comparables. Additionally, it assumes dividends fully reflect the company's ability to generate shareholder value, which is less relevant for a capital-intensive, innovation-driven company like Pfizer. For these reasons, we consider the DDM unreliable for our analysis.

Relative Valuation


Estimated Share Price: \$22.78 Implied Return: -9.08%

	EPS			
Company	2025E	EPS 2026E	P/E 25	P/E 26
AMGN	\$21.06	\$21.56	14.09	13.76
BMY	\$4.59	\$4.90	11.47	10.74
GILD	\$6.41	\$7.26	19.19	16.94
GSK	\$4.42	\$4.85	10.59	9.65
JNJ	\$11.04	\$10.36	18.60	19.82
LLY	\$22.50	\$30.64	40.00	29.38
MRK	\$8.02	\$8.66	10.46	9.69
VRTX	\$15.33	\$18.27	27.51	23.08
		Average	18.99	16.63
PFE	\$1.40	\$1.37	17.93	18.29

Relative Valuation uses 1-year forward Price-to-Earnings (P/E) comparisons between Pfizer and a select peer group of pharmaceutical companies. Given that the pharmaceutical industry is diverse and very competitive, there is not a perfectly comparable company. As a result, we considered different pharmaceutical companies in terms of similar size, geographic presence, and exposure to core therapeutic areas such as oncology, immunology, and vaccines.

Key peers include Amgen, Bristol Myers Squibb, Gilead, and Eli Lilly. This model primarily uses P/E to estimate Pfizer's equity value relative to the group. While it provides a useful market-based benchmark, the method has limitations in the pharmaceutical sector. A significant portion of a company's value stems from its drug pipeline rather than currently marketed products, meaning multiples based on current earnings may understate future profitability. Additionally, differences in patent lifecycles between companies can skew comparisons, as revenue from blockbuster drugs can decline sharply upon patent expiration.

We view the relative valuation model as a useful crosscheck on our DCF estimate. Comparing Pfizer to a peer group highlights how the market currently prices companies with similar size, geographic reach, and therapeutic focus. While it does not capture companyspecific pipeline prospects or patent lifecycles, it provides a market-based benchmark for investor expectations. In combination with the DCF, it helps validate whether our intrinsic value estimate is in line with comparable firms. We see this model as complementary, offering perspective on relative market positioning rather than absolute value.



Source: Pfizer 10-K [2]

Revenue projections were based on growth trends across key business units, assuming year-over-year increases for growing medicines only of 10% in oncology, 5% in specialty medicines, and 4% in primary care, excluding products facing patent expirations or other declines. These rates reflect historical performance and align with the forecasted annual growth rates for these sub-industries [12]. Individual drugs were then adjusted from these base rates based on upcoming patent expirations, historical drug performance, and forecasts relating to that specific drug's treated condition. For anticipated patent expirations, an 80% decline in sales was applied in the first year, which is consistent with estimates due to immediate competition from generic brands [5].


A category related to upcoming drugs from Pfizer's pipeline was also included in the forecast. This line item represents future drugs that will be approved and placed into production into the future. Without this included, decreasing revenue from expired products would not be balanced by revenues from new products and instead lead to understated revenue. This estimate was based calculated using the amount of revenue lost from patent expirations

multiplied by a 3% growth rate, a conservative estimate forward, depreciation is projected to remain relatively lower than the expected growth rate for existing drugs to represent lag in replacement times.

All things considered, we forecast revenue to grow from \$63.6B in 2024 to \$89.4B in 2034, representing a 3.46% CAGR. This long-term growth is driven by an 8.72% CAGR in the oncology division as sales increase from \$15.6B in 2024 to \$36.0B in 2034. This high growth rate is consistent with industry forecasts because of the rising global cancer rate, high pricing power in the oncology market, and fewer generic threats. Primary care is projected to be the lowest performing segment with a CAGR of 4.2%. This segment underperforms because of patent expirations of the popular drugs Eliquis and Prevnar.

Expenses

Pfizer's expenses reflect the costs needed to expand its pipeline while also funding existing drugs through production and distribution. Cost of Sales has historically represented approximately 17-18% of revenues, but it spiked to nearly 36% in 2021 due to one-time adjustments and potentially higher production costs associated with COVID-19 vaccine manufacturing [2]. Moving forward, Cost of Sales is projected to stabilize around 21-22% of revenues, reflecting efficiency gains and scaling of production across the company's diverse product lines.



Source: Pfizer 10-K [2], Team estimates

Depreciation shows a notable spike from 2022 onwards, increasing from \$1.5B in 2021 to \$5.1B in 2022 [2]. This is largely tied to capital expenditures on manufacturing facilities, particularly for biologics and vaccine production, as well as investments in new technologies to support Pfizer's oncology and specialty medicines pipeline. Going

stable as the bulk of these assets are fully operational.

Pfizer's SG&A expenses and R&D spending are also largely consistent with post-COVID numbers. SG&A has consistently represented ~25% of revenues [2], funding marketing, commercial operations, and support functions. R&D remains a critical investment, averaging 17% of revenues, and works with acquired in-process R&D to accelerate pipeline development. Amortization is driven by the amount of intangible assets on Pfizer's books which we project to stay consistent as they are needed to secure exclusivity in the marketplace and develop new drugs.

Provision / (Benefit) for Taxes on Income

Our forecast models tax expense using a 20% effective tax rate. This is a reasonable estimate because Pfizer's historical volatility is largely driven by one-time temporary items like restructuring charges, acquisition-related costs, and COVID-related revenue swings, rather than changes to its underlying tax structure. Once these non-recurring effects are removed, Pfizer's tax structure aligns with other large U.S. pharmaceutical companies, which normally carries an effective tax rate ranging from 17-22% due to foreign income, R&D credits, and FDII benefits [31]. Analysts also commonly normalize Pfizer's tax rate around this range, making 20% consistent with peer assumptions and long-term planning. As Pfizer's business mix stabilizes post-COVID and recent acquisitions are absorbed, its effective tax rate should converge toward this steady-state level, making 20% a defensible and realistic modeling choice.

Profitability

Pfizer's Profit Margin Over Time



Source: Pfizer 10-K [2], Team estimates

Pfizer's profitability improves steadily in our model because most of the unusual cost and revenue spikes from the COVID era unwind and the company returns to a more traditional pharmaceutical cost structure with items like Cost of Sales returning to historical levels. This is caused by a shift toward higher-margin areas like oncology and specialty medicines. To ensure that operating margins better reflect the core business activities, we exclude certain non-recurring items from the income statement, including other income (related to pensions and retirement plans) and restructuring charges.

Our projected margin profile is reasonable because it reflects Pfizer's return to its core business mix and aligns with historical performance, and industry expectations. Pfizer's operating margin has historically been an average of 23% before COVID. We project net income to grow from \$8.0B in 2024 to \$19.1B in 2034 [2], driven by stabilizing costs and the growth in oncology and specialty care.

CapEx

Pfizer has strategically expanded its pipeline through acquisitions. In late 2023, the company completed the acquisition of Seagen for \$43B, gaining access to Seagen's leading anti-body drug technology to strengthen its oncology portfolio [32]. More recently, Pfizer completed the acquisition of Metsera for \$10B, enhancing its presence in medicines for obesity and cardiometabolic therapies [33]. These deals reflect Pfizer's strategy of achieving high growth from acquisitions and inorganic means.

Beyond acquisitions, Pfizer continues to invest significantly in its own operations. In 2024, the company spent roughly \$6.5B on Property, Plant, and Equipment (PP&E) to support manufacturing and R&D infrastructure [2]. The model forecasts consistent spending on PP&E with projected annual CapEx around \$3.2B.

WACC Estimation

Risk free rate	4.32%
Beta	0.42
Equity risk premium	5.48%
Cost of equity	6.33%
Cost of debt, pretax	4.71%
Marginal tax rate	22.00%
Cost of debt, post-tax	3.67%
Weight of equity	88.43%
Weight of debt	11.57%
WACC	6.28%

Source: Pfizer 10-K [2], Team estimates

- Cost of equity was calculated using the CAPM
- Risk free rate was based on interpolated yield on U.S. Treasury zero-coupon issues in 2024.
- ❖ Beta was calculated using the average weekly raw beta of historical returns from the past 2-5 years.
- ❖ Equity risk premium (ERP) is based on the historical average ERP between 2016-2025.
- Cost of debt is based on YTM on Pfizer's 10-year corporate bond.
- ❖ <u>Marginal tax rate</u> is based on an estimate of U.S. federal and state corporate tax rate.
- Pfizer has no preferred stock.
- Pfizer does not report operating leases separately.

Capital Structure

Historically, Pfizer carried relatively high leverage, with its debt-to-equity ratio peaking at 1.87 in 2016 and falling to its low of 1.06 in 2022. It has risen to 1.41 in 2024 [2]. Looking ahead in our forecast, the model projects further de-levering as the debt-to-equity ratio declines steadily towards 0.63 in 2034, signaling the company will choose to use equity as its primary financing method.

Sensitivity Analysis

To determine which variables have the highest influence on valuation, they are tested against each other using the What-If Analysis in Excel. To determine how sensitive valuation is, we divided the Change in Value/Change in Variable to come up with a number that represents how much valuation would change if the underlying variable was increased by 1%.

Impact of Variable on Valuation

CV Growth of NOPLAT	3.00
WACC	(1.30)
COGS as % of Sales	(0.75)
SGA as % of Sales	(0.73)
Risk Free Rate	(0.67)
Equity Risk Premium	(0.52)
Beta	(0.16)
Pre-Tax Cost of Debt	(0.13)
Effective Tax Rate	(0.13)
1-Year Sales Decline After Patent Expira	tion (0.13)
Cost of Equity	0.03
Current Dividend Yield	(0.02)

Source: Team estimates

Overall, according to our calculations, CV Growth of NOPLAT is the most influential variable. A 1% increase in the perpetual growth rate of NOPLAT would raise valuation by 3.00%. This is expected because the terminal value largely determines the DCP and EP valuation. Meanwhile, the WACC is the most sensitive risk variable. A 1% increase in WACC would result in a 1.30% decrease in the valuation. This highlights that Pfizer's cost of capital and debt management are critical factors in the company's valuation.

Beta vs. Equity Risk Premium

					Beta			
	23.08	0.12	0.22	0.32	0.42	0.52	0.62	0.72
	6.48%	59.26	35.99	25.51	19.54	15.67	12.96	10.95
Ħ	6.23%	61.05	37.27	26.49	20.33	16.33	13.53	11.45
Ē	5.98%	62.96	38.63	27.53	21.17	17.05	14.15	12.00
Pre	5.73%	64.98	40.08	28.66	22.09	17.82	14.82	12.59
sk	5.48%	67.13	41.65	29.87	23.08	18.65	15.54	13.22
Equity Risk Premium	5.23%	69.43	43.33	31.18	24.15	19.56	16.32	13.92
į.	4.98%	71.88	45.15	32.60	25.31	20.54	17.18	14.67
Eq	4.73%	74.51	47.12	34.16	26.59	21.63	18.12	15.50
	4.48%	77.33	49.26	35.85	27.99	22.81	19.15	16.41

Sensitivity testing shows the model is slightly more sensitive to beta than the equity risk premium. A 1% increase in beta would decrease valuation by approximately 0.16%, whereas a 1% increase in the equity risk premium would reduce value by 0.52%. While both are marketdriven assumptions, beta has a slightly more noticeable effect on valuation, reflecting its role in determining the cost of equity and discounting cash flows, whereas equity risk premium adjustments are largely buffered by the underlying cash flow assumptions.

Risk Free Rate vs. Pre-Tax Cost of Debt

			Risk Free Rate 2.82% 3.32% 3.82% 4.32% 4.82% 5.32% 5.82%												
	23.08	2.82%	3.32%	5.32%	5.82%										
ebt	7.71%	44.60	32.25	25.06	20.34	17.01	14.53	12.61							
Ũ	6.71%	48.34	34.24	26.29	21.19	17.63	15.00	12.98							
Cost of Debt	5.71%	52.73	36.47	27.65	22.10	18.28	15.49	13.37							
Č	4.71%	57.94	39.00	29.13	23.08	18.98	16.01	13.77							
ах	3.71%	64.24	41.86	30.77	24.14	19.72	16.57	14.20							
Pre-Tax	2.71%	72.00	45.16	32.59	25.29	20.52	17.15	14.64							
Ţ	1.71%	81.80	48.97	34.61	26.54	21.37	17.77	15.12							

Valuation is moderately sensitive to financing assumptions. A 1% increase in the risk-free rate would reduce enterprise value by about 0.67%, while the same increase in the pretax cost of debt would lower value by 0.13%. This shows that while borrowing costs do influence the weighted average cost of capital, overall valuation is more sensitive to broad shifts in discount rates represented by the risk-free rate.

COGS as % of Sales vs. Effective Tax Rate

				COG	S as % of S	Sales		
	23.08	18.59%	19.59%	20.59%	21.59%	22.59%	23.59%	24.59%
te	40.0%	18.86	18.10	17.33	16.57	15.80	15.04	14.27
Effective Tax Rate	35.0%	20.66	19.82	18.98	18.15	17.31	16.47	15.63
	30.0%	22.50	21.58	20.67	19.76	18.84	17.93	17.01
	25.0%	24.37	23.38	22.39	21.40	20.41	19.42	18.43
	20.0%	26.29	25.22	24.15	23.08	22.01	20.94	19.87
	15.0%	28.24	27.09	25.94	24.79	23.64	22.49	21.34
Ξ	10.0%	30.24	29.00	27.77	26.54	25.30	24.07	22.83

Operational and fiscal assumptions are important levers for valuation. Increasing COGS by 1% decreases valuation by 0.75%, highlighting the direct impact of margin erosion on enterprise value. In contrast, a 1% increase in the effective tax rate reduces valuation by 0.13%, indicating that while taxes matter, operating efficiency has a more pronounced effect on cash flows and overall value.

Cost of Equity vs. Current Dividend Yield

				C	ost of Equi	ty	_	
	23.08	3.6%	4.6%	5.6%	6.6%	8.6%	10.6%	12.6%
Current Dividend Yield	10.1%	21.64	21.84	22.05	22.26	22.67	23.08	23.48
	9.1%	21.84	22.05	22.26	22.46	22.87	23.28	23.69
	8.1%	22.05	22.26	22.46	22.67	23.08	23.48	23.89
	7.1%	22.26	22.46	22.67	22.87	23.28	23.69	24.09
Ž	6.1%	22.46	22.67	22.87	23.08	23.48	23.89	24.30
t D	5.1%	22.67	22.87	23.08	23.28	23.69	24.09	24.50
ren	4.1%	22.87	23.08	23.28	23.48	23.89	24.30	24.70
Ä	3.1%	23.08	23.28	23.48	23.69	24.09	24.50	24.90
0	2.1%	23.28	23.48	23.69	23.89	24.30	24.70	25.10

Valuation is relatively insensitive to both cost of equity and dividend assumptions in this model. A 1% increase in cost of equity decreases valuation by only 0.03%, while a 1% increase in the current dividend yield lowers it by 0.02%.

These small sensitivities suggest that within the tested ranges, expected returns and payout assumptions are minor drivers compared with operational and growth factors.

SGA as % of Sales vs. WACC

				SGA	as % of S	ales		
	23.08	19%	21%	23%	25%	27%	29%	31%
	7.8%	16.73	15.43	14.13	12.83	11.54	10.24	8.94
C	7.3%	19.70	18.20	16.71	15.21	13.72	12.22	10.73
	6.8%	23.73	21.97	20.20	18.44	16.68	14.92	13.16
WACC	6.3%	29.52	27.37	25.23	23.08	20.94	18.80	16.65
W	5.8%	38.55	35.81	33.07	30.32	27.58	24.84	22.10
	5.3%	54.63	50.82	47.02	43.21	39.40	35.59	31.78
	4.8%	91.31	85.07	78.82	72.58	66.34	60.10	53.86

Operational efficiency and capital structure assumptions strongly influence valuation. Raising SGA by 1% reduces value by 0.74%, while increasing WACC by 1% lowers valuation by 1.30%. This illustrates that managing operating expenses and minimizing discount rates are key levers for sustaining enterprise value, with WACC having the largest proportional effect across the model.

CV Growth of NOPLAT vs. 1-Year Sales Decline After Patent Expiration

				CV Gr	owth of NC	PLAT		
	23.08	2.50%	3.00%	3.50%	4.00%	4.50%	5.00%	5.50%
ne	-62.50%	14.59	16.67	19.50	23.58	29.94	41.25	67.01
Decline	-67.50%	14.49	16.56	19.38	23.43	29.76	41.02	66.64
	-72.50%	14.39	16.45	19.26	23.29	29.58	40.78	66.27
Sales	-77.50%	14.29	16.35	19.13	23.15	29.41	40.55	65.91
r S	-80.00%	14.25	16.29	19.07	23.08	29.32	40.44	65.73
1-Year	-82.50%	14.20	16.24	19.01	23.01	29.24	40.32	65.55
1.	-87.50%	14.10	16.13	18.90	22.87	29.07	40.10	65.20
	-92.50%	14.01	16.03	18.78	22.73	28.90	39.88	64.85
	-97.50%	13.92	15.93	18.66	22.59	28.73	39.65	64.51

Long-term growth and near-term revenue shocks are the most impactful drivers of value. A 1% increase in CV growth of NOPLAT raises valuation by 3.0%, reflecting the compounding power of sustained profitability. In contrast, a 1% increase in the 1-year sales decline from patent expiration reduces valuation by 0.13%, showing that short-term shocks have smaller proportional effects than long-term growth assumptions, though they remain important to monitor.

Conclusion

Given the assumptions and estimations in our we have made, we recommend a **SELL** rating for Pfizer, as our valuation indicates that the stock is overvalued relative to its intrinsic worth. Our DCF and EP analysis produce a target price of **\$23.08**, reflecting Pfizer's future cash flow, capital investments, and high cost of capital. While the DDM suggests a higher value of \$61.58, we consider this

approach unreliable, as it ignores substantial R&D expenditures, working capital requirements, and capital-intensive investments critical to the company's long-term pipeline development. Finally, Pfizer is generally underperforming based on the multiple valuations relative to peers.

Team Disclosure

We assign a BUY rating when a security is expected to deliver returns greater than the industry-specific threshold (typically 10-15%) over the next twelve months. A SELL rating is given when the security's target price is below the current price over the next twelve months, while a HOLD rating implies a return somewhere in between 0% and the industry specific threshold.

Important Disclaimer

This report was created by students enrolled in the Applied Equity Valuation (FIN:4250) class at the University of Iowa. The report was originally created to offer an internal investment recommendation for the University of Iowa Krause Fund and its advisory board. The report also provides potential employers and other interested parties an example of the students' skills, knowledge and abilities. Members of the Krause Fund are not registered investment brokers or officially licensed advisors. professionals. The investment advice contained in this report does not represent an offer or solicitation to buy or sell any of the securities mentioned. Unless otherwise noted, facts and figures included in this report are from publicly available sources. This report is not a complete compilation of data, and its accuracy is not guaranteed. From time to time, the University of Iowa, its faculty, staff, students, or the Krause Fund may hold a financial interest in the companies mentioned in this report.

References

- 1. Pfizer. (2025). *History*.
- https://www.pfizer.com/about/history
- 2. Pfizer. (2024). Form 10-K.

https://s206.q4cdn.com/795948973/files/doc_financials/20 24/ar/10K Final.pdf

- 3. Pfizer. (2025). *Product List*. https://www.pfizer.com/products/product-list
- 4. The White House. (2025, November 6). Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
- 5. Congressional Research Service. (2012, March 2). *Drug Patent Expirations: Potential Effects on Pharmaceutical Innovation*.

 $https://www2.law.umaryland.edu/marshall/crsreports/crsd\ ocuments/R42399_03022012.pdf$

- 6. Pfizer. (2025). *New Drug Development Pipeline*. https://www.pfizer.com/science/drug-product-pipeline
- 7. FactSet. (2025). *Pfizer Inc. Snapshot*. https://my.apps.factset.com/workstation/
 8. Pfizer. (2025). *Form 10-Q*. https://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/029df2a4-9496-4b4c-8b86-dbc5eff1479a.pdf
- 9. Pfizer. (2025). *Dividend & Split History*. https://investors.pfizer.com/Investors/Stock-Info/dividend-split-history/default.aspx
- 10. Pfizer. (2025). *Fact Sheet*. https://www.pfizer.com/news/media-resources/press-kits/corporate-media-kit
- 11. Good Jobs First. (2025). *Violation Tracker Current Parent Company Summary*. https://violationtracker.goodjobsfirst.org/parent/pfizer

- 12. S&P NetAdvantage. (October 2025). *Industry Surveys: Pharmaceuticals*. https://www-capitaliq-com.proxy.lib.uiowa.edu/CIQDotNet/Research/Investment Research.aspx
- 13. National Library of Medicine. (2023, July 10). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10385763/

14. IRS. (2012, December 7). *Guidance for Computing Substantiating Pharmaceutical Drugs*.

https://www.irs.gov/businesses/guidance-for-computing-substantiating-pharmaceutical-drugs-therapeutic-biologics

- 15. Pew Research Center. (2024, March 21). New weightloss drugs surge in popularity amid obesity surge in U.S. https://www.pewresearch.org/short-reads/2024/03/21/as-obesity-rates-rise-in-the-us-and-worldwide-new-weightloss-drugs-surge-in-popularity/
- 16. CNN Business. (2024, November 14). *Moderna, Pfizer, Novavax stocks tumble after Trump picks RFK Jr. for Health Secretary.*

https://www.cnn.com/2024/11/14/business/vaccine-maker-stocks-tumble-rfk-jr-health-secretary

17. Pfizer. (2025, September 30). Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaches-landmark-agreement-us-government-lower-drug

- 18. FDA. (2024). *Novel Drug Approvals for 2024*. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- 19. EMA. (2025, January 16). *Human medicines in 2024*. https://www.ema.europa.eu/en/news/human-medicines-2024
- 20. IQVIA Institute for Human Data Science. (January 2024). *Global Use of Medicines: Outlook to 2028*. https://www.iqvia.com/-/media/iqvia/pdfs/china/viewpoints/iqvia-institute-general-use-of-medicines-2024-for-print.pdf

21. Pfizer. (2025, July 24). *Pfizer Completes Licensing Agreement with 3SBio*.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio

22. PopulationPyramid.net. (2024). *Population of United States of America 2024*.

https://www.populationpyramid.net/united-states-of-america/

23. UNFPA. (2025). *Population Data Portal*. https://pdp.unfpa.org/?data_id=dataSource_8-5%3A17306%2CdataSource_8-0%3A586%2CdataSource_2-0%3A4&page=Visualization-Overview

- 24. Statista. (2024, March 4). *Obesity Is Rising in the U.S.* https://www.statista.com/chart/11497/obesity-in-the-us/
- 25. Pharmaceutical Executive. (2025, May 13). *GLP-1* Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports.

https://www.pharmexec.com/view/glp-1-surge-fuels-10-2-rise-us-prescription-drug-spending-2024

- 26. FDA. (2023, June 12). Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
- 27. Washington Examiner. (2024, September 26). *RFK Jr. bashes Ozempic buzz and Novo Nordisk profits*. https://www.washingtonexaminer.com/policy/healthcare/3 167388/rfk-jr-bashes-ozempic-buzz-novo-nordisk-profits/
- 28. Federal Reserve Bank of St. Louis. (2025, October 24). Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average (CPIMEDSL). https://fred.stlouisfed.org/series/CPIMEDSL
- 29. Center on Budget and Policy Priorities. (2025, August 27). By the Numbers: Harmful Republican Megabill Will Take Health Coverage Away From Millions of People and Raise Families' Costs.

https://www.cbpp.org/research/health/by-the-numbers-harmful-republican-megabill-will-take-health-coverage-away-from

- 30. World Bank. (2022). Research and development expenditure (% of GDP) United States. https://data.worldbank.org/indicator/GB.XPD.RSDV.GD. ZS?locations=US
- 31. Tax Notes. (2024, December 18). *The Pharmaceutical Industry: Effective Tax Rates Before and After the TCJA*. https://www.taxnotes.com/special-reports/tax-cuts-and-jobs-act/pharmaceutical-industry-effective-tax-rates-and-after-tcja/2024/12/17/7nfny
- 32. Pfizer. (2023, March 13). *Pfizer Invests \$43 Billion to Battle Cancer*. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer
- 33. Pfizer. (2025, November 13). *Pfizer Completes Acquisition of Metsera*.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera

- 34. BioSpace. (2025, October 9). Nearly Three Quarters of FDA Breakthrough Designated Drugs Win Approval: Report. https://www.biospace.com/fda/nearly-three-quarters-of-fda-breakthrough-designated-drugs-win-approval-report
- 35. National Library of Medicine. (2022, February 11). Why 90% of clinical drug development fails and how to improve it?

https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/

36. National Library of Medicine. (2021, April 8). Changing FDA Approval Standards: Ethical Implications for Patient Consent.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8029608/

- 37. Pfizer. (2024). *Pfizer's Year in Review*. https://annualreview.pfizer.com/
- 38. Pfizer. (2025, October 9). *Pfizer Declares Fourth-Quarter 2025 Dividend*.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2025-dividend

39. Macrotrends. (2025). *U.S. Life Expectancy (1950-2025)*. https://www.macrotrends.net/global-metrics/countries/usa/united-states/life-expectancy

- 40. BioSpace. (2023, October 16). *Pfizer Kicks Off \$3.5B Cost-Cutting Program as COVID Revenues Decline*. https://www.biospace.com/pfizer-kicks-off-3-5b-cost-cutting-program-as-covid-revenues-decline
- 41. FiercePharma. (2025, April 29). *Pfizer, in sweeping cost cutting push, lifts overall savings target to \$7.7B.* https://www.fiercepharma.com/pharma/pfizer-sweeping-cost-cutting-push-lifts-savings-target-77b
- 42. Pfizer. (2025, November 4). *Pfizer's Solid Q3 2025 Performance*. https://insights.pfizer.com/q3-2025-earnings
- 43. Pfizer. (2025, November 4). *Pfizer Quarterly Corporate Performance Third Quarter 2025*. https://investors.pfizer.com/Investors/Events--Presentations/event-details/2025/Pfizer-Quarterly-Corporate-Performance---Third-Quarter-2025-2025-imdILplSOF/default.aspx
- 44. ASPE. (2023, August 29). Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program. https://aspe.hhs.gov/reports/ira-research-series-medicare-drug-price-negotiation-program

Pfizer Inc. Revenue Decomposition Millions of Dollars	•													
Fiscal Years Ending Dec. 31	Expiration	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Total Revenues		100,330	59,553	63,627	64,957	62,126	65,493	69,090	72,519	75,576	78,783	82,218	85,672	89,355
^YoY Growth		23.4%	-40.6%	11.0%	2.1%	-4.4%	5.4%	5.5%	5.0%	4.2%	4.2%	4.4%	4.2%	4.3%
Pfizer Innovative Health (pre-2019) Pfizer Essential Health (pre-2019)					7,890	6,358								
Global Biopharmaceuticals Business		98,988 24.4%	58,237 -41.2%	62,400 7.1%	63,788 2.2%	60,925 -4.5%	64,173 5.3%	67,603 5.3%	70,888 4.9%	73,915 4.3%	77,090 4.3%	80,490 4.4%	83,906 4.2%	87,549 4.3%
Primary Care/Vaccines	•	73,023	30,799	30,135	29,175	23,329	23,408	23,688	24,053	24,451	24,877	25,331	25,814	26,327
^YoY Growth	2026	40.6%	-57.8%	-2.2%	-3.2%	-20.0%	0.3%	1.2%	1.5%	1.7%	1.7%	1.8%	1.9%	2.0%
Eliquis ^YoY Growth	2026	6,480 8.5%	6,747 4.1%	7,366 9.2%	7,661 4.0%	1,532 -80.0%	1,501 -2.0%	1,471 -2.0%	1,442 -2.0%	1,413 -2.0%	1,385 -2.0%	1,357 -2.0%	1,330 -2.0%	1,303 -2.0%
Prevnar family	2026	6,342	6,501	6,411	6,869	1,374	1,346	1,319	1,293	1,267	1,242	1,217	1,193	1,169
^YoY Growth		20.3%	2.5%	-1.4%	7.1%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Paxlovid	2041	18,933	1,279	5,716	5,887	6,005	6,065	6,065	6,005	5,885	5,767	5,652	5,538	5,428
^YoY Growth Comirnaty	2041	24811.8% 37,809	<i>-93.2%</i> 11,220	346.9% 5,353	<i>3.0%</i> 3,215	2.0% 2,175	1.0% 1,636	<i>0.0%</i> 1,355	-1.0% 1,225	-2.0% 1,201	-2.0% 1,177	-2.0% 1,153	-2.0% 1,130	-2.0% 1,108
^YoY Growth	2041	2.8%	-70.3%	-52.3%	-39.9%	-32.4%	-24.8%	-17.2%	-9.6%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Nurtec ODT/Vydura	2030 (Pending 2034)	213	928	1,263	1,314	1,366	1,421	1,478	1,537	307	301	295	289	283
^YoY Growth	2025 (5. 1: 2027)	0.0%	335.7%	36.1%	4.0%	4.0%	4.0%	4.0%	4.0%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%
Abrysvo ^YoY Growth	2036 (Pending 2037)	0.0%	890 0.0%	755 -15.2%	717 -5.1%	685 -4.4%	659 -3.8%	637 -3.2%	621 -2.6%	608 -2.0%	596 -2.0%	584 -2.0%	573 -2.0%	561 -2.0%
Premarin family		455	397	380	334	301	276	260	249	244	239	235	230	225
^YoY Growth		-19.2%	-12.7%	-4.3%	-12.1%	-10.1%	-8.0%	-6.0%	-4.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
BMP2		277	338	352	388	422	454	484	509	529	550	572	595	619
^YoY Growth		4.1%	22.0%	4.1%	10.1%	8.9%	7.7%	6.4%	5.2%	4.0%	4.0%	4.0%	4.0%	4.0%
FSME-IMMUN/TicoVac ^YoY Growth		200 8.1%	268 34.0%	280 4.5%	303 8.3%	326 7.4%	347 6.6%	367 5.7%	385 4.9%	400 4.0%	416 4.0%	433 4.0%	450 4.0%	468 4.0%
All other Primary Care		2,473	2,233	2,259	2,488	2,709	2,917	3,106	3,268	3,399	3,535	3,676	3,823	3,976
^YoY Growth		38.9%	-9.7%	1.2%	10.1%	8.9%	7.7%	6.5%	5.2%	4.0%	4.0%	4.0%	4.0%	4.0%
Primary Care/Vaccine Medicines Enter	ing Pipeline	42.022	14.000	16.652	47.444	6,435	6,784	7,146	7,520	9,198	9,669	10,157	10,662	11,186
Specialty Care ^YoY Growth		13,833 17.9%	14,988 8.3%	16,652 11.1%	17,141 2.9%	17,993 5.0%	18,883 <i>4.9%</i>	19,827 5.0%	20,723 4.5%	21,545 4.0%	22,398 4.0%	23,292 4.0%	24,229 4.0%	25,207 4.0%
Vyndaqel family	2025 (Pending 2028)	2,447	3,321	5,451	1,090	1,068	1,047	1,026	1.006	985	966	946	928	909
^YoY Growth		21.4%	35.7%	64.1%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Xeljanz	2026	1,796	1,703	1,168	921	184	181 -2.0%	177	173	170 -2.0%	167 -2.0%	163 -2.0%	160 -2.0%	157
^YoY Growth Enbrel (Outside the U.S. and Can	a(2028	-26.8% 1,003	-5.2% 830	-31.4% 690	-21.1% 576	- <i>80.0%</i> 498	-2.0% 445	<i>-2.0%</i> 89	-2.0% * 87	-2.0% 85	-2.0% 84	-2.0% 82	-2.0% 80	-2.0% 79
^YoY Growth	412020	-15.4%	-17.2%	-16.9%	-16.5%	-13.6%	-10.7%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Sulperazon		786	757	637	628	618	607	596	585	573	562	550	539	529
^YoY Growth	2024 (5 1: 2024)	15.1%	-3.7%	-15.9%	-1.5%	-1.6%	-1.7%	-1.8%	-1.9%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Zavicefta ^YoY Growth	2031 (Pending 2034)	412 -0.2%	511 24.0%	586 14.7%	661 12.8%	736 11.3%	807 <i>9.7%</i>	872 8.1%	930 <i>6.6%</i>	976 5.0%	195 -80.0%	191 -2.0%	188 -2.0%	184 -2.0%
Octagam(c)		186	245	509	598	687	773	850	913	959	1,007	1,057	1,110	1,166
^YoY Growth		0.0%	31.7%	107.8%	17.4%	14.9%	12.5%	10.0%	7.5%	5.0%	5.0%	5.0%	5.0%	5.0%
Inflectra		532	490	509	470	439	415	398	385	377	370	363	355	348
^YoY Growth Zithromax		-19.0% 331	-7.9% 406	3.9% 480	-7.7% 576	- <i>6.5%</i> 674	-5.4% 768	-4.3% 852	-3.1% 921	-2.0% 967	-2.0% 1,015	-2.0% 1,066	-2.0% 1,119	-2.0% 1,175
^YoY Growth		19.1%	22.7%	18.2%	20.0%	17.0%	14.0%	11.0%	8.0%	5.0%	5.0%	5.0%	5.0%	5.0%
Genotropin		360	539	470	516	562	606	648	687	721	757	795	835	877
^YoY Growth		-7.5%	49.7%	-12.8%	9.8%	8.9%	7.9%	6.9%	6.0%	5.0%	5.0%	5.0%	5.0%	5.0%
BeneFIX ^YoY Growth		425 -3.0%	424 -0.2%	381 -10.1%	364 -4.4%	350 -4.0%	338 -3.5%	327 -3.0%	319 -2.5%	313 -2.0%	307 -2.0%	301 -2.0%	295 -2.0%	289 -2.0%
Cibingo	2034 (Pending 2036)	-3.0% 27	-0.2% 128	215	247	278	308	336	359	377	396	416	437	-2.0%
^YoY Growth		0.0%	374.1%	68.0%	14.7%	12.8%	10.8%	8.9%	6.9%	5.0%	5.0%	5.0%	5.0%	-80.0%
Oxbryta(d)		73	328	201	222	242	262	281	298	313	329	345	362	380
^YoY Growth		0.0%	349.3%	-38.7%	10.4%	9.3%	8.2%	7.1%	6.1%	5.0%	5.0%	5.0%	5.0%	5.0%
All other Hospital(e) ^YoY Growth		4,730 <i>96.1%</i>	4,514 -4.6%	4,448 -1.5% ▼	4,893 10.0%	5,334 <i>9.0%</i>	5,761 8.0%	6,164 7.0%	6,534 <i>6.0%</i>	6,861 5.0%	7,204 5.0%	7,564 <i>5.0%</i>	7,942 5.0%	8,340 5. <i>0</i> %
All other Specialty Care		743	792	907	800	722	665	626	601	589	578	566	555	544
^YoY Growth		-56.3%	6.6%	14.5%	-11.7%	-9.8%	-7.8%	-5.9%	-3.9%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Specialty Care Medicines Entering Pipe	line				4,579	5,601	5,900	6,583	6,924	7,277	8,463	8,886	9,324	10,145

Fiscal Years Ending Dec. 31	Expiration	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Oncology		12,132	12,450	15,612	17,473	19,602	21,882	24,088	26,111	27,918	29,815	31,867	33,863	36,015
^YoY Growth		-1.6%	2.6%	25.4%	11.9%	12.2%	11.6%	10.1%	8.4%	6.9%	6.8%	6.9%	6.3%	6.4%
Ibrance	2027	5,120	4,753	4,367	4,060	3,815	763	748	733	718	704	690	676	662
^YoY Growth		-5.8%	-7.2%	-8.1%	-7.0%	-6.0%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Xtandi(f)	2027	1,650	1,659	2,039	2,465	2,867	573	562	551	540	529	518	508	498
^YoY Growth		39.2%	0.5%	22.9%	20.9%	16.3%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Padcev	2033	_	53	1,588	2,048	2,543	3,036	3,478	3,819	4,010	4,210	4,421	884	867
^YoY Growth		0.0%	0.0%	2896.2%	29.0%	24.2%	19.4%	14.6%	9.8%	5.0%	5.0%	5.0%	-80.0%	-2.0%
Adcetris		-	56	1,089	1,647	2,355	3,173	4,014	4,747	5,221	5,743	6,318	6,950	7,645
^YoY Growth		0.0%	0.0%	1844.6%	51.2%	43.0%	34.7%	26.5%	18.2%	10.0%	10.0%	10.0%	10.0%	10.0%
Oncology biosimilars(g)		1,753	1,407	1,037	878	767	690	639	609	597	585	574	562	551
^YoY Growth		0.0%	-19.7%	-26.3%	-15.3%	-12.7%	-10.0%	-7.3%	-4.7%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Inlyta	2026	1,003	1,036	978	971	194	190	186	183	179	176	172	169	165
^YoY Growth		0.1%	3.3%	-5.6%	-0.7%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Lorbrena	2033	343	539	731	957	1,213	1,486	1,760	2,009	2,210	2,431	2,674	535	524
^YoY Growth		0.0%	57.1%	35.6%	30.9%	26.7%	22.6%	18.4%	14.2%	10.0%	10.0%	10.0%	-80.0%	-2.0%
Bosulif		575	645	645	685	733	790	857	936	1,029	1,132	1,245	1,370	1,507
^YoY Growth	_	6.5%	12.2%	0.0%	6.2%	7.0%	7.7%	8.5%	9.2%	10.0%	10.0%	10.0%	10.0%	10.0%
Braftovi/Mektovi	2030 (Pending 2031)	456	477	607	739	749	607	368	149	30	29	29	28	27
^YoY Growth		33.3%	4.6%	27.3%	21.7%	1.4%	-19.0%	-39.3%	-59.7%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%
Tukysa	2031 (Pending 2034)	-	18	480	562	650	743	839	934	1,028	206	201	197	193
^YoY Growth		0.0%	0.0%	2566.7%	17.1%	15.7%	14.3%	12.8%	11.4%	10.0%	-80.0%	-2.0%	-2.0%	-2.0%
Elrexfio	2036 (Pending 2037)	-	10	133	160	188	218	249	279	307	338	371	408	449
^YoY Growth		0.0%	0.0%	1230.0%	20.0%	18.0%	16.0%	14.0%	12.0%	10.0%	10.0%	10.0%	10.0%	10.0%
Tivdak	2033	-	4	131	157	185	215	245	275	302	332	366	73	72
^YoY Growth		0.0%	0.0%	3175.0%	20.0%	18.0%	16.0%	14.0%	12.0%	10.0%	10.0%	10.0%	-80.0%	-2.0%
Talzenna	2029 (Pending 2032)	48	64	117	140	162	180	193	39	38	37	36	36	35
^YoY Growth		0.0%	33.3%	82.8%	20.0%	15.6%	11.2%	6.8%	-80.0%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
All other Oncology		1,846	1,729	1,670	2,004	2,365	2,743	3,127	3,502	3,853	4,238	4,662	5,128	5,641
^YoY Growth		675.6%	-6.3%	-3.4%	20.0%	18.0%	16.0%	14.0%	12.0%	10.0%	10.0%	10.0%	10.0%	10.0%
Oncology Medicines Entering Pipe	eline					815	6,473	6,823	7,348	7,857	9,125	9,590	16,340	17,180
Pfizer Centreone		1,342	1,272	1,146	1,002	898	823	772	740	726	711	697	683	669
^YoY Growth		-22.5%	-5.2%	-9.9%	-12.5%	-10.4%	-8.3%	-6.2%	-4.1%	-2.0%	-2.0%	-2.0%	-2.0%	-2.0%
Pfizer Ignite		7	44	82	166	304	497	715	891	935	982	1,031	1,082	1,137
^YoY Growth		0.0%	528.6%	86.4%	102.5%	83.0%	63.5%	44.0%	24.5%	5.0%	5.0%	5.0%	5.0%	5.0%
Alliance Devenues (Inch. 1-1 Ab)	0.527	7.502	0.200	0.272	0.427	0.552	0.751	0.038	0.380	0.765	10.155	10.562	10.084
Alliance Revenues (Included Abov	vej	8,537	7,582	8,388	8,372	8,427	8,552	8,751	9,028	9,389 4.0%	9,765 4.0%	10,155 4.0%	10,562 4.0%	10,984
^YoY Growth)	0.0%	-11.2%	10.6%	-0.2%	0.7%	1.5%	2.3%	3.2%					4.0%
Royalty Revenues (Included Abov ^YoY Growth	rej	845	1,058	1,423	1,706	1,992	2,261	2,495	2,675	2,782	2,893	3,009	3,129	3,254
		0.0%	25.2% 50,914	<i>34.5%</i> 53,816	19.9%	16.7%	13.5%	<i>10.4%</i> 57,844	7.2% 60,816	4.0% 63,405	<i>4.0%</i> 66,125	4.0%	4.0%	<i>4.0%</i> 75,117
Product Revenues		91,793	50,914	55,810	54,878	51,708	54,679	37,844	00,810	03,405	00,125	69,054	71,981	/5,11/

Misc Other

Biosimilars

Hospira Infusion

Consumer Health Care Business

Notes:

Impact of patent expiration

Adjusted values so it continues to decline rather than suddenly grow Forecasted additions to pipeline

Income Statement

Millions of Dollars, except per share data

Fiscal Years Ending Dec. 31 2022 2023 2024 2025E 2026E 2027E 2028E 2029E 2030E 2031E 2032E 2033E 2034E Revenues: 91.793 \$ 50.914 \$ 53.816 54.878 51.708 54.679 57.844 60.816 63.405 66.125 69.054 71.981 75.117 Product revenues 8,372 10,984 Alliance revenues 8,537 7,582 8,388 8,427 8,552 8,751 9,028 9,389 9,765 10,155 10,562 845 1,058 1,706 1,992 2,495 2,675 2,782 2,893 3,009 3,254 Royalty revenues 1,423 2,261 3,129 101.175 59,554 63,627 64,957 62.126 65,493 69,090 72.519 75,576 78.783 82.218 85.672 89.355 **Total Revenues** Costs and expenses: Cost of Sales (Minus Depreciation) 29,280 18,664 10,838 14,026 13,415 14,141 14,918 15,658 16,319 17,011 17,753 18,499 19,294 **^%** of Revenues 28.9% 31.3% 17.0% 21.6% 21.6% 21.6% 21.6% 21.6% 21.6% 21.6% 21.6% 21.6% 21.6% 5,064 6,290 7,013 3,454 3,419 3,350 3,303 3,270 3,267 3,274 3,285 3,302 Depreciation 3,287 34.0% 38.7% 18.8% 18.8% 18.8% 18.8% 18.8% 18.8% 18.8% 18.8% 18.8% 18.8% ^% of PPE 37.0% Selling, informational and administrative expenses 13.677 14.771 14.730 16.216 15.510 16.350 17.248 18.104 18.867 19.668 20.525 21.388 22.307 **1%** of Revenues 13.5% 24.8% 23.2% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% Amortization of intangible assets 3,609 4,733 5,286 4,838 4.716 4.125 3,776 2,829 3,871 3,871 3,871 3,871 3,871 8.9% ^% of Intangible Assets 8.3% 7.3% 9.5% 9.6% 10.3% 9.5% 8.7% 6.5% 8.9% 8.9% 8.9% 8.9% 11,428 10,679 10,567 13,984 15,198 Research and development expenses 10,822 11,048 11,139 11,751 12,334 12,854 13,400 14,571 11.3% 17.9% 17.0% 17.0% 17.0% 17.0% **^%** of Revenues 17.0% 17.0% 17.0% 17.0% 17.0% 17.0% 17.0% Acquired in-process research and development expe 953 194 108 926.44 886.07 934.09 985.40 1.034.29 1.077.89 1.123.63 1.172.63 1.221.88 1.274.42 **^%** of Revenues 0.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% Restructuring charges and certain acquisition-related 1.375 2.943 2,419 1,338 1,280 1.349 1,423 1.494 1,557 1,623 1.694 1.765 1,841 1.4% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 1% of Revenues 4.9% 3.8% 2.1% 2.1% 2.1% 2.1% Other (income) / deductions--net (ex. Interest exp) 75 (363)1,842 1,842 1,658 1,474 1,289 1,105 921 737 553 368 _ Earnings Before Interest & Taxes 35,714 1,643 10,569 11,268 10,677 12,630 14,396 16,673 16,838 18,082 19,392 20,703 22,267 Interest (Income) (251)(1,624)(545)(821)(684)(906)(1,202)(1,510)(1,892)(2,303)(2,772)(3,301)(3,890)Interest Expense 1,238 2,209 3,091 2,327 2,135 2,073 2,059 2,083 2,101 2,121 2,144 2,167 2,191 34.727 **Earnings Before Taxes** 1.058 8,023 9.762 9.226 11.464 13.540 16.100 16,629 18,264 20.020 21.837 23.966 Provision / (benefit) for taxes on income 3,328 (1,115)(28)1,952 1,845 2,293 2,708 3,220 3,326 3,653 4,004 4,367 4,793 -105.4% 20.0% ^% of EBT 9.6% -0.3% 20.0% 20.0% 20.0% 20.0% 20.0% Income from continuing operations 31,399 2,173 8,051 7,810 7,381 9,171 10,832 12,880 13,303 14,611 16,016 17,469 19,173 Discontinued operations--net of tax 6 (15)11 ^YoY Growth -101.4% -350.0% -173.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 9,171 14,611 19,173 Net income before allocation to noncontrolling interests 31,405 2,158 8,062 7,810 7,381 10,832 12,880 13,303 16,016 17,469 Less: Net income attributable to noncontrolling interests (35)(39)(31)(31)(34)(38)(42)(46)(51)(57)(63)(69)(76)-13.7% -14.2% -10.5% -10.5% -10.5% ^% of Equity Attributable to NCI 9,133 12,834 Net income attributable to Pfizer Inc. common shareholders \$ 31,370 \$ 2,119 \$ 8,031 \$ 7,779 \$ 7,347 \$ \$ 10,790 \$ \$ 13,252 \$ 14,555 \$ 15,954 \$ 17,400 \$ 19,096 Other information: Total shares outstanding 5,616 5,646 5,667 5,463 5,264 5,065 4,868 4,672 4,477 4,283 4,091 3,899 3,709 Weighted Average Shares Outstanding 5,618 5,631 5,657 5,565 5,363 5,164 4,967 4,770 4,575 4,380 4,187 3,995 3,804 5.02 5.58 \$ 0.38 \$ 1.42 \$ 1.40 Ś 1.37 \$ 1.77 S 2.17 \$ 2.69 Ś 2.90 Ś 3.32 Ś 3.81 \$ 4.36 \$ Ś 1.64 \$ Dividends per share 1.60 1.68 \$ 1.72 \$ 1.76 Ś 1.80 Ś 1.84 \$ 1.88 Ś 1.92 Ś 1.96 Ś 2.00 Ś 2.04 \$ 2.08 **Total Dividends** 8,983 9,247 9,512 9.572 9.440 9.296 9.139 8,968 8,783 8,585 8.374 8.150 7.913

Source: FactSet, Pfizer 10-K (p. 51)

Notes:

Other income is related to pension/retirement plans - Flatlined

Pfizer Inc. **Balance Sheet** Millions of Dollars iscal Years Ending Dec. 31 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E 2026E 2027E 2028F 2029F 2030E 2031E Assets 1,139 \$ 1,784 \$ 1,944 \$ Cash and cash equivalents \$ 3,343 \$ 3,641 \$ 2,595 \$ 1,342 \$ 1,121 \$ 416 \$ 2,853 \$ 1,043 \$ (3,536) \$ 1,777 \$ 9,110 \$ 16,733 \$ 26,374 \$ 36,787 \$ 48,763 \$ 62,352 18.650 17.694 8.525 10.437 22.316 9.837 21.619 22,401 23.211 Short-term investments 32,779 19.649 15.255 29.125 19.434 20 137 20.865 24 050 24 920 25 821 Trade accounts receivable, net of 8.669 8,176 8,225 8,221 8,025 6,772 7,930 11,479 10,952 11,566 11,463 10,328 9,878 10,413 10,985 11,530 12,016 12,526 13,072 6,783 7,578 7,508 7,068 8,046 10,851 8,766 9,749 10,233 10,664 11,601 Inventories 5,663 7,513 9.059 8,981 10,189 9,166 9.241 11.116 Current deferred tax assets 4.498 2.662 3.041 3.050 3.374 2.736 3.264 4.266 3.577 3.978 3.314 (1.131)(1.069)(1.328)(1.568)(1.865)(1.926)(2.115)(2,319)2,750 2,301 6,581 3,820 4,902 Other current assets 2,163 3,050 12,186 3,605 5,017 4,911 4,253 4,407 4,566 4,731 5,080 5,263 5,454 **Total Current Assets** 57,702 43,804 38,949 41,142 49,926 32,803 35,066 59,693 51,259 43,334 50,358 39,371 44,784 53,787 63,202 74,563 86,855 100,664 116,179 Equity-method investments 17,133 16,856 16,472 11,033 11,637 217 225 233 241 250 259 269 278 Long-term investments 17,518 15,999 7,116 7,015 2,767 3,014 3,406 5,054 4,036 3,731 2,010 2,097 2,187 2,282 2,380 2,483 2,591 2,703 Property, plant and equipment, r 11,762 13,766 13,318 13,865 13,385 12,969 13,900 14,882 16,274 18,940 18,393 18,208 17,839 17,588 17,503 17,416 17,397 17,434 17,493 Identifiable intangible assets, net 35,166 40,356 52,648 48,741 35,211 33,936 28,471 25,146 43,370 64,900 55,411 50,573 45,857 43,460 43,460 43,460 43,460 43,460 43,460 Goodwill 42,069 48,242 54,449 55,952 53,411 48,202 49,577 49,208 51,375 67,783 68,527 68,527 68,527 68,527 68,527 68,527 68,527 68,527 68,527 Noncurrent deferred tax assets a 1,544 1,794 1,812 1,855 1,924 1,911 2,383 3,341 6,693 3,706 8,662 7,796 6,930 6,063 5,197 4,331 3,465 2,599

7,679

13,163

12,471

9,817

7,450

7,125

7,511

7,924

8.317

8.668

9.036

17,626

4,569

2,799

Total Assets	\$ 169,274	\$ 167.381	\$ 171.615	5 171.797	\$ 159,423	\$ 167,594	\$ 154,228	\$ 181,475	\$ 197,203	\$ 226,502	\$ 213,395	5 194.246	\$ 193,482	\$ 199,460	208,443	219.356	\$ 231,231	\$ 244,700	\$ 259,928	\$ 276,868 \$	295,917
•	+,	+,	+ -:-,		,		7,	+,	+,	7,	+ ===,		,	,			+,	+ =,	+/	, ,	
Liabilities and Equity																					
Short-term borrowings, including	\$ 5,141	\$ 10,159	\$ 10,688	9,953	\$ 8,831	\$ 16,195	\$ 2,703	\$ 2,241	\$ 2,945	\$ 10,350	\$ 6,946	5,396	5,408	5,618	5,844	6,060	6,296	6,527	6,769	7,016	7,272
^% of Non-Cash Current Assets	10.3%	27.1%	32.1%	27.1%	19.4%	55.9%	9.0%	4.2%	6.2%	28.4%	15.1%	12.6%	12.6%	12.6%	12.6%	12.6%	12.6%	12.6%	12.6%	12.6%	12.6%
Trade accounts payable	3,440	3,620	4,536	4,656	4,674	3,887	4,309	5,578	6,809	6,710	5,633	5,437	5,200	5,482	5,783	6,070	6,326	6,594	6,882	7,171	7,479
Dividends payable	1,711	1,852	1,944	2,029	2,047	2,104	2,162	2,249	2,303	2,372	2,437	2,393	2,360	2,324	2,285	2,242	2,196	2,146	2,094	2,037	1,978
Income taxes payable	531	418	437	477	1,265	980	1,049	1,266	1,587	2,349	2,910	-398	(377)	(468)	(553)	(657)	(679)	(745)	(817)	(891)	(978)
Accrued compensation and relate	1,784	2,359	2,487	2,196	2,397	2,390	3,058	3,332	3,407	2,776	3,838	3,313	3,169	3,340	3,524	3,699	3,855	4,018	4,193	4,370	4,557
Deferred revenues		-	-	-	-	-	-	3,067	2,520	2,700	1,511	1,916	1,833	1,932	2,038	2,139	2,230	2,324	2,426	2,527	2,636
^% of Sales	0%	0%	0%	0%	0%	0%	0%	4%	3%	3%	2%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%
Other current liabilities	9,024	10,990	11,023	11,115	12,643	11,747	12,640	24,939	22,568	20,537	19,720	15,833	15,143	15,963	16,840	17,676	18,421	19,203	20,040	20,882	21,780
^% of Sales	14%	17%	18%	17%	18%	16%	17%	32%	27%	24%	22%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%
Total Current Liabilities	21,631	29,398	31,115	30,426	31,857	37,303	25,921	42,672	42,139	47,794	42,995	33,889	32,736	34,192	35,761	37,229	38,645	40,067	41,586	43,112	44,725
Long-term debt	31,541	28,740	31,398	33,538	32,909	35,955	37,133	36,195	32,884	61,538	57,405	53,637	51,908	51,315	51,759	52,043	52,371	52,755	53,148	53,564	54,023
^% of Non-Cash Assets	20%	18%	19%	20%	21%	22%	25%	21%	17%	28%	27%	27.7%	27.7%	27.6%	27.7%	27.7%	27.7%	27.7%	27.7%	27.7%	27.7%
Pension and postretirement ben	10,264	8,119	8,172	7,430	6,610	6,217	5,411	3,724	2,250	2,167	2,115	1,904	1,692	1,481	1,269	1,058	846	635	423	212	-
Noncurrent deferred tax liabilitie	24,981	26,877	30,753	3,900	3,700	5,652	4,063	349	1,023	640	2,122	1,698	1,273	849	424	-	-	-	-	-	-
^% of Tax Expense Deferred		95%	345%	297%	75%	335%	-429%	-201%	20%	34%	-5293%										
Other taxes payable	4,353	3,992	4,000	18,697	14,737	12,126	11,560	11,331	9,812	8,534	6,112	4	40.00/	40.00/	40.00/	42.20/	40.00/	-	40.00/	-	- 20/
^YoY % Change	4.000	-8.3%	0.2%	367.4%	-21.2%	-17.7%	-4.7%	-2.0%	-13.4%	-13.0%	-28.4%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%	-13.2%
Other noncurrent liabilities	4,883	5,257	6,337	6,149	5,850	6,894	6,669	9,743	13,180	16,539	14,150	11,080	10,597	11,171	11,785 17.1%	12,370	12,891 <i>17.1%</i>	13,438	14,024	14,613	15,241
^% of Sales Total Liabilities	8%	8%	10%	9%	95,663	10%	9%	12%	16%	19%	16%	17.1%	17.1%	17.1%		17.1%		17.1%	17.1%	17.1%	17.1%
Total Liabilities	97,653	102,383	111,775	100,140	95,663	104,147	90,757	104,014	101,288	137,212	124,899	102,212	98,206	99,008	100,998	102,699	104,752	106,895	109,181	111,501	113,989
Commitments and Contingencies																					
APIC + Common stock, \$0.05 par	79,461	81,501	83,170	84,763	86,739	87,913	89,144	91,064	92,278	93,109	94,083	94,093	94,104	94,114	94,124	94,135	94,145	94,155	94,166	94,176	94,186
Treasury stock, shares at cost: 20	(73,021)	(79,252)	(84,364)	(89,425)	(101,610)	(110,801)	(110,988)	(111,361)	(113,969)	(114,487)	(114,763)	(109,473)	(104,183)	(98,893)	(93,603)	(88,313)	(83,023)	(77,733)	(72,443)	(67,153)	(61,863)
Retained earnings	72,176	71,993	71,774	85,291	89,554	97,670	96,770	103,394	125,656	118,353	116,725	114,931	112,838	112,675	114,327	118,193	122,662	128,632	136,211	145,461	156,645
Accumulated other comprehensi	(7,316)	(9,522)	(11,036)	(9,321)	(11,275)	(11,640)	(11,688)	(5,897)	(8,304)	(7,961)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)	(7,842)
Total PFE's Stockholders Equity	71,300	64,720	59,544	71,308	63,408	63,142	63,238	77,200	95,661	89,014	88,203	91,709	94,917	100,054	107,006	116,172	125,942	137,212	150,092	164,642	181,127
Equity attributable to noncontrol	321	278	296	348	351	303	235	262	256	274	294	325	359	397	439	485	536	593	656	725	801

Source: FactSet, Pfizer 10-K (p. 53)

Total Liabilities and Equity

Total Equity

Other noncurrent assets

3,513

71,621

64,998

59,840

71,656

63,759

63,445

\$ 169,274 \$ 167,381 \$ 171,615 \$ 171,796 \$ 159,422 \$ 167,592 \$ 154,230 \$ 181,476 \$ 197,205 \$ 226,500 \$ 213,396 \$

63,473

77,462

95,917

89,288

88,497

92,034

95,276

100,451

3,420

3,323

3,227

Notes:

116,658

194,246 \$ 193,482 \$ 199,460 \$ 208,443 \$ 219,356 \$ 231,231 \$ 244,700 \$ 259,928 \$ 276,868 \$

126,478

107,445

Negative cash in 2025E is not possible Intangible assets floored at the past 5 year average Other noncurrent assets noted as sales related on 10-K Dividends payable based on dividend payout ratio Pension and postretirement amortized on a 10 year horizon Other taxes payable floored at 0

137,805

150,747

165,367

181,928

295,917

2032E

5,651

288

2,819

1,732

9,430

Ś

2033E

77,572 \$

26.755

13,621

12,088

(2.529)

5,855

299

2,941

17,587

43,460

68,527

9.826

866

133,363

2034E

94.769

27 722

14,207

12,608

(2.776)

6,067

310

3,068

17,706

43,460 68,527

10,248

0

152,598

Pfizer Inc.
Forecasted Cash Flow Statement

Fiscal Years Ending Dec. 31	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Operating Cash Flows													
Net Income	31,370	2,119	8,031	7,779	7,347	9,133	10,790	12,834	13,252	14,555	15,954	17,400	19,096
Plus Depreciation & Amortization	8,673	11,023	12,299	8,292	8,135	7,475	7,079	6,116	7,142	7,138	7,145	7,156	7,174
	2,010	,	,	-,	5,255	.,	1,010	5,225	7,2 12	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	7,2 10	7,200	.,
Change in Accounts Receivable	527	(614)	103	1,135	450	(535)	(572)	(545)	(486)	(510)	(546)	(549)	(586)
Change in Inventory	78	(1,208)	(662)	1,685	399	(475)	(508)	(484)	(431)	(453)	(485)	(487)	(520)
Change in Current Deferred Tax Ass	689	(401)	664	4,445	(62)	259	240	297	61	189	203	210	247
Change in Noncurrent Tax Assets	(3,352)	2,987	(4,956)	866	866	866	866	866	866	866	866	866	866
Change in Accounts Payable	1,231	(99)	(1,077)	(196)	(237)	282	301	287	256	268	288	289	308
Change in Income Taxes Payable	321	762	561	(3,308)	22	(91)	(85)	(104)	(22)	(67)	(72)	(74)	(87)
Change in Accrued Compensation	75	(631)	1,062	(525)	(144)	172	183	175	156	164	175	176	188
Change in Deferred Revenue	(547)	180	(1,189)	405	(84)	99	106	101	90	95	101	102	109
Change in Other Current Liabilities	(2,371)	(2,031)	(817)	(3,887)	(690)	821	877	836	745	782	837	842	898
Change in Pension Benefits	(1,474)	(83)	(52)	(212)	(212)	(212)	(212)	(212)	(212)	(212)	(212)	(212)	(212)
Change in Noncurrent Deferred Tax	674	(383)	1,482	(424)	(424)	(424)	(424)	(424)	-	-	-	-	-
Change in Other Taxes Payable	(1,519)	(1,278)	(2,422)	(6,108)	(4)	_	-	-	_	_	_	_	_
,	() ,	(, ,	() ,	, ,	()								
Change in Accumulated Other Comp	(2,407)	343	119	-	-	-	-	-	-	-	-	-	-
Cash Flow From Operations	31,968	10,686	13,146	9,947	15,363	17,369	18,642	19,741	21,418	22,816	24,255	25,720	27,482
Investing Cash Flows	4					4	4		4				4
Change in Other Current Assets	(1,197)	106	658	(154)	(159)	(165)	(171)	(177)	(184)	(190)	(197)	(204)	(212)
Change in ST Investments	6,809	12,479	(9,597)	(703)	(728)	(754)	(782)	(810)	(839)	(870)	(901)	(934)	(967)
Change in Equity Method Investmen	5,439	(604)	11,420	(8)	(8)	(8)	(9)	(9)	(9)	(10)	(10)	(10)	(11)
Change in LT Investments	1,018	305	1,721	(87)	(91)	(94)	(99)	(103)	(107)	(112)	(117)	(122)	(127)
Change in Net PPE - Depreciation	(6,456)	(8,956)	(6,466)	(3,268)	(3,050)	(3,098)	(3,217)	(3,200)	(3,251)	(3,304)	(3,333)	(3,378)	(3,422)
Change in Identifiable Intangible As	(21,833)	(26,263)	4,203	-	-	(1,728)	(3,776)	(2,829)	(3,871)	(3,871)	(3,871)	(3,871)	(3,871)
Change in Goodwill	(2,167)	(16,408)	(744)	-	-	-	-	-	-	-	-	-	-
Change in Other Noncurrent Assets	(5,484)	692	2,654	2,367	325	(386)	(413)	(393)	(351)	(368)	(394)	(396)	(422)
Cash Flow From Investing	(17,190)	(39,447)	537	(1,853)	(3,712)	(6,235)	(8,466)	(7,521)	(8,613)	(8,724)	(8,823)	(8,916)	(9,033)
Financing Cash Flows													
Change in ST Borrowings	704	7,405	(3,404)	(1,550)	13	210	225	216	236	231	242	247	256
Change in Dividends Payable	54	69	65	(44)	(33)	(36)	(39)	(43)	(46)	(49)	(53)	(56)	(59)
Change in LT Debt	(3,311)	28,654	(4,133)	(3,768)	(1,730)	(593)	443	284	328	384	392	416	459
Ü	() ,	,	() ,	, ,	() /	,							
Dividends Paid	(8,983)	(9,247)	(9,512)	(9,572)	(9,440)	(9,296)	(9,139)	(8,968)	(8,783)	(8,585)	(8,374)	(8,150)	(7,913)
Change in APIC + CS	1,214	831	974	10	10	10	10	10	10	10	10	10	10
Change in Treasury Stock	(2,608)	(518)	(276)	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290
Change in NCI	(6)	18	20	31	34	38	42	46	51	57	63	69	76
Change in Other Noncurrent Liabilit	3,437	3,359	(2,389)	(3,070)	(483)	574	614	585	521	547	586	589	628
Cash Flow From Financing	(12,936)	27,212	(16,266)	(12,673)	(6,338)	(3,802)	(2,553)	(2,579)	(2,392)	(2,116)	(1,844)	(1,584)	(1,252)

Pfizer Inc.

Common Size Income Statement

Fiscal Years Ending Dec. 31	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Revenues:													
Product revenues	90.7%	85.5%	84.6%	84.5%	83.2%	83.5%	83.7%	83.9%	83.9%	83.9%	84.0%	84.0%	84.1%
Alliance revenues	8.4%	12.7%	13.2%	12.9%	13.6%	13.1%	12.7%	12.4%	12.4%	12.4%	12.4%	12.3%	12.3%
Royalty revenues	0.8%	1.8%	2.2%	2.6%	3.2%	3.5%	3.6%	3.7%	3.7%	3.7%	3.7%	3.7%	3.6%
Total Revenues	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Costs and expenses:	0.0%	0.0%	0.0%										
Cost of sales (ex. D&A)	28.9%	31.3%	17.0%	21.6%	21.6%	21.6%	21.6%	21.6%	21.6%	21.6%	21.6%	21.6%	21.6%
Depreciation & Amortizatio	5.0%	10.6%	11.0%	12.8%	13.1%	11.4%	10.2%	8.4%	9.4%	9.1%	8.7%	8.4%	8.0%
Selling, informational and a	13.5%	24.8%	23.2%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%	25.0%
Research and development	11.3%	17.9%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%
Acquired in-process researc	0.9%	0.3%	0.2%	1.4%	1.4%	1.4%	1.4%	1.4%	1.4%	1.4%	1.4%	1.4%	1.4%
Amortization of intangible a	3.6%	7.9%	8.3%	7.4%	7.6%	6.3%	5.5%	3.9%	5.1%	4.9%	4.7%	4.5%	4.3%
Restructuring charges and c	1.4%	4.9%	3.8%	2.1%	2.1%	2.1%	2.1%	2.1%	2.1%	2.1%	2.1%	2.1%	2.1%
Other income/ (deductions)_	0.1%	-0.6%	2.9%	2.8%	2.7%	2.3%	1.9%	1.5%	1.2%	0.9%	0.7%	0.4%	0.0%
Earnings Before Interest & Taxes	35.3%	2.8%	16.6%	17.3%	17.2%	19.3%	20.8%	23.0%	22.3%	23.0%	23.6%	24.2%	24.9%
Interest (Income)	-0.2%	-2.7%	-0.9%	-1.3%	-1.1%	-1.4%	-1.7%	-2.1%	-2.5%	-2.9%	-3.4%	-3.9%	-4.4%
Interest Expense	1.2%	3.7%	4.9%	3.6%	3.4%	3.2%	3.0%	2.9%	2.8%	2.7%	2.6%	2.5%	2.5%
Income from continuing operations	34.3%	1.8%	12.6%	15.0%	14.9%	17.5%	19.6%	22.2%	22.0%	23.2%	24.4%	25.5%	26.8%
(Provision) / benefit for taxes on inc	3.3%	-1.9%	0.0%	3.0%	3.0%	3.5%	3.9%	4.4%	4.4%	4.6%	4.9%	5.1%	5.4%
Income from continuing operations	31.0%	3.6%	12.7%	12.0%	11.9%	14.0%	15.7%	17.8%	17.6%	18.5%	19.5%	20.4%	21.5%
Discontinued operationsnet of tax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income before allocation to nor	31.0%	3.6%	12.7%	12.0%	11.9%	14.0%	15.7%	17.8%	17.6%	18.5%	19.5%	20.4%	21.5%
Less: Net income attributable to noi	0.0%	-0.1%	0.0%	0.0%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%
Net income attributable to Pfizer Inc	31.0%	3.6%	12.6%	12.0%	11.8%	13.9%	15.6%	17.7%	17.5%	18.5%	19.4%	20.3%	21.4%

Fiscal Years Ending Dec. 31	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
<u>Assets</u>													
Cash and cash equivalents	0.4%	4.8%	1.6%	-5.4%	2.9%	13.9%	24.2%	36.4%	48.7%	61.9%	75.8%	90.5%	106.1%
Short-term investments	22.1%	16.5%	30.5%	31.0%	33.6%	33.0%	32.4%	32.0%	31.8%	31.6%	31.4%	31.2%	31.0%
Trade accounts receivable, net of al	10.8%	19.4%	18.0%	15.9%	15.9%	15.9%	15.9%	15.9%	15.9%	15.9%	15.9%	15.9%	15.9%
Inventories	8.9%	17.1%	17.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%	14.1%
Current tax assets	3.5%	6.7%	5.2%	-1.7%	-1.7%	-2.0%	-2.3%	-2.6%	-2.5%	-2.7%	-2.8%	-3.0%	-3.1%
Other current assets	5.0%	8.2%	6.7%	6.8%	7.3%	7.2%	7.1%	7.0%	7.0%	6.9%	6.9%	6.8%	6.8%
Total current assets	50.7%	72.8%	79.1%	60.6%	72.1%	82.1%	91.5%	102.8%	114.9%	127.8%	141.3%	155.7%	170.8%
Equity-method investments	10.9%	19.5%	0.3%	0.3%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.3%	0.3%
Long-term investments	4.0%	6.3%	3.2%	3.2%	3.5%	3.5%	3.4%	3.4%	3.4%	3.4%	3.4%	3.4%	3.4%
Property, plant and equipment, net		31.8%				26.9%	25.3%			22.1%			19.8%
	16.1%		28.9%	28.0%	28.7%			24.0%	23.0%		21.3%	20.5%	
Identifiable intangible assets, net	42.9%	109.0%	87.1%	77.9%	73.8%	66.4%	62.9%	59.9%	57.5%	55.2%	52.9%	50.7%	48.6%
Goodwill Noncurrent deferred tax assets and	50.8% 6.6%	113.8% 6.2%	107.7% 13.6%	105.5% 12.0%	110.3% 11.2%	104.6% 9.3%	99.2% 7.5%	94.5% 6.0%	90.7% 4.6%	87.0% 3.3%	83.3% 2.1%	80.0%	76.7% 0.0%
Other noncurrent assets	13.0%	20.9%	15.4%	11.5%	11.5%	9.3% 11.5%	11.5%	11.5%	11.5%	3.3% 11.5%	11.5%	1.0% 11.5%	11.5%
Total assets	194.9%	380.3%	335.4%	299.0%	311.4%	304.6%	301.7%	302.5%	306.0%	310.6%	316.1%	323.2%	331.2%
10(a) assets	134.370	300.370	333.470	233.070	311.470	304.070	301.770	302.370	300.070	310.070	310.170	323.270	331.270
<u>Liabilities and Equity</u>	-	-	-										
Short-term borrowings, including cu	2.9%	17.4%	10.9%	8.3%	8.7%	8.6%	8.5%	8.4%	8.3%	8.3%	8.2%	8.2%	8.1%
Trade accounts payable	6.7%	11.3%	8.9%	8.4%	8.4%	8.4%	8.4%	8.4%	8.4%	8.4%	8.4%	8.4%	8.4%
Dividends payable	2.3%	4.0%	3.8%	3.7%	3.8%	3.5%	3.3%	3.1%	2.9%	2.7%	2.5%	2.4%	2.2%
Income taxes payable	1.6%	3.9%	4.6%	-0.6%	-0.6%	-0.7%	-0.8%	-0.9%	-0.9%	-0.9%	-1.0%	-1.0%	-1.1%
Accrued compensation and related	3.4%	4.7%	6.0%	5.1%	5.1%	5.1%	5.1%	5.1%	5.1%	5.1%	5.1%	5.1%	5.1%
Deferred revenues	2.5%	4.5%	2.4%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%
Other current liabilities	22.3%	34.5%	31.0%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%	24.4%
Total current liabilities	41.6%	80.3%	67.6%	52.2%	52.7%	52.2%	51.8%	51.3%	51.1%	50.9%	50.6%	50.3%	50.1%
Long-term debt	32.5%	103.3%	90.2%	82.6%	83.6%	78.4%	74.9%	71.8%	69.3%	67.0%	64.6%	62.5%	60.5%
Pension and postretirement benefit	2.2%	3.6%	3.3%	2.9%	2.7%	2.3%	1.8%	1.5%	1.1%	0.8%	0.5%	0.2%	-
Noncurrent deferred tax liabilities	1.0%	1.1%	3.3%	2.6%	2.0%	1.3%	0.6%	-		-	-	-	_
Other taxes payable	9.7%	14.3%	9.6%	0.0%	-	-	-	_	_	_	_	_	_
Other noncurrent liabilities	13.0%	27.8%	22.2%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%
Total liabilities	100.1%	230.4%	196.3%	157.4%	158.1%	151.2%	146.2%	141.6%	138.6%	135.7%	132.8%	130.1%	127.6%
Committee and Co. II													
Commitments and Contingencies	- 04 20/	456.20/	- 4.47.00/	-	454.504	4.42.70/	426.224	- 420.00/	-	- 440 504	-	400.00/	405.404
APIC + Common stock, \$0.05 par val	91.2%	156.3%	147.9%	144.9%	151.5%	143.7%	136.2%	129.8%	124.6%	119.5%	114.5%	109.9%	105.4%
Treasury stock, shares at cost: 2024	-112.6%	-192.2%	-180.4%	-168.5%	-167.7%	-151.0%	-135.5%	-121.8%	-109.9%	-98.7%	-88.1%	-78.4%	-69.2%
Retained earnings	124.2%	198.7%	183.5%	176.9%	181.6%	172.0%	165.5%	163.0%	162.3%	163.3%	165.7%	169.8%	175.3%
Accumulated other comprehensive	-8.2%	-13.4%	-12.3%	-12.1%	-12.6%	-12.0%	-11.4%	-10.8%	-10.4%	-10.0%	-9.5%	-9.2%	-8.8%
Total Pfizer Inc. shareholders' eq	94.6%	149.5%	138.6%	141.2%	152.8%	152.8%	154.9%	160.2%	166.6%	174.2%	182.6%	192.2%	202.7%
Equity attributable to noncontrollin	0.3%	0.5%	0.5%	0.5%	0.6%	0.6%	0.6%	0.7%	0.7%	0.8%	0.8%	0.8%	0.9%
Total equity	94.8%	149.9%	139.1%	141.7%	153.4%	153.4%	155.5%	160.9%	167.4%	174.9%	183.4%	193.0%	203.6%
Total liabilities and equity	194.9%	380.3%	335.4%	299.0%	311.4%	304.6%	301.7%	302.5%	306.0%	310.6%	316.1%	323.2%	331.2%

Weighted Average Cost of Capital (WACC) Estimation

E	stimated WACC	6.28%
Market Value of the Firm	556,053	100.00%
MV of Total Debt	64,351	11.57% wD
Long-Term Debt	57,405	
ST borrowings, including current portio	6,946	
Market Value of Debt:		
MV of Equity	491,702	88.43% wE
Current Stock Price	\$25.06	
Total Shares Outstanding	19,621	
Market Value of Common Equity:		MV Weights
After-Tax Cost of Debt	3.67%	
Marginal Tax Rate	22%	
Pre-Tax Cost of Debt	4.71%	YTM on company's 10-year corporate bond
Implied Default Premium	0.39%	
Risk-Free Rate	4.32%	Based on interpolated yield on U.S. Treasury zero-coupon iss
Cost of Debt:		
Cost of Equity	6.63%	
Equity Risk Premium	5.48%	Historical average ERP for the period 2016-2025
Beta	0.42	Average of 2, 3, 4, and 5 year weekly beta (raw beta)
Risk-Free Rate	4.32%	Based on interpolated yield on U.S. Treasury zero-coupon iss
Cost of Equity:		ASSUMPTIONS:

Discounted Cash Flow (DCF) and Economic Profit (EP) Valuation Models

Key Inputs:

Value of Equity

Shares Outstanding

Intrinsic Value of Last FYE

Implied Price as of Today

450,559 19,621

22.96

23.08

CV Growth of NOPLAT	4.00%
CV Year ROIC	34.78%
WACC	6.28%
Cost of Equity	6.63%

WACC Cost of Equity	6.28% 6.63%									
Fiscal Years Ending Dec. 31	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
DCF Model:										
Free Cash Flow (FCF)	13,390	14,596	15,425	14,145	15,780	15,815	16,674	17,559	18,360	19,256
Continuing Value (CV)										714,252
PV of FCF	12,598	12,921	12,847	11,085	11,635	10,972	10,883	10,783	10,609	412,703
Value of Operating Assets:	517,036									
Non-Operating Adjustments:										
+ Excess Cash	1,006									
+ Short-term investments	19,434									
+ Equity-method investments	217									
+ Long-term investments	2,010									
- Short-Term Borrowings	(6,946)			-						
- Long-Term Debt	(57,405)									
- Pension and postretirement ben	(2,115)									
- Noncurrent deferred tax liabilitie	(2,122)									
- Other taxes payable	(6,112)									
- Other noncurrent liabilities	(14,150)									
- Equity attributable to noncontro_	(294)									
Value of Equity	450,559									
Shares Outstanding	19,621									
Intrinsic Value of Last FYE	22.96									
Implied Price as of Today	23.08									
EP Model:										
Economic Profit (EP)	6,931	6,342	7,991	9,454	11,169	11,595	12,437	13,328	14,212	15,103
Continuing Value (CV)										661,246
PV of EP	6,521	5,614	6,656	7,409	8,235	8,044	8,118	8,185	8,212	382,075
Total PV of EP	449,069									
Invested Capital (last FYE)	67,967									
Value of Operating Assets:	517,036									
Non-Operating Adjustments:										
+ Excess Cash	1,006									
+ Short-term investments	19,434									
+ Equity-method investments	217									
+ Long-term investments	2,010									
- Short-Term Borrowings	(6,946)									
- Long-Term Debt	(57,405)									
- Pension and postretirement ben	(2,115)									
- Noncurrent deferred tax liabilitie	(2,122)									
- Other taxes payable	(6,112)									
- Other noncurrent liabilities	(14,150)									
- Equity attributable to noncontro_	(294)									

Pfizer Inc.Dividend Discount Model (DDM) or Fundamental P/E Valuation Model

Fiscal Years Ending	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
EPS	\$ 1.40 \$	1.37 \$	1.77 \$	2.17 \$	2.69 \$	2.90 \$	3.32 \$	3.81 \$	4.36 \$	5.02
Key Assumptions CV growth of EPS CV Year ROE Cost of Equity	2.50% 8.82% 6.63%									
Future Cash Flows P/E Multiple (CV Year) EPS (CV Year) Future Stock Price									\$	17.37 5.02 87.18
Dividends Per Share Discounted Cash Flows	\$ 1.72 \$ 1.61 \$	1.76 \$ 1.55 \$	1.80 \$ 1.48 \$	1.84 \$ 1.42 \$	1.88 \$ 1.36 \$	1.92 \$ 1.31 \$	1.96 \$ 1.25 \$	2.00 \$ 1.20 \$	2.04 1.15 \$	48.94
Intrinsic Value as of Last FYE Implied Price as of Today	 61.27 61.58									

Pfizer Inc. *Relative Valuation Models*

			EPS	EPS			Est. 5yr		
Ticker	Company	Price	2025E	2026E	P/E 25	P/E 26	EPS gr.	PEG 25	PEG 26
AMGN	Amgen	\$296.70	\$21.06	\$21.56	14.09	13.76	24.3	0.58	0.57
BMY	Bristol Myers Squibb Co	\$52.65	\$4.59	\$4.90	11.47	10.74	5.1	2.25	2.11
GILD	Gilead Sciences Inc	\$123.00	\$6.41	\$7.26	19.19	16.94	11.0	1.75	1.55
GSK	GSK PLC	\$46.82	\$4.42	\$4.85	10.59	9.65	5.7	1.86	1.69
JNJ	Johnson & Johnson	\$205.33	\$11.04	\$10.36	18.60	19.82	14.2	1.31	1.39
LLY	Eli Lilly & Co	\$900.05	\$22.50	\$30.64	40.00	29.38	49.3	0.81	0.60
MRK	Merck & Co	\$83.88	\$8.02	\$8.66	10.46	9.69	9.6	1.09	1.01
VRTX	Vertex Pharmaceuticals Inc	\$421.67	\$15.33	\$18.27	27.51	23.08	25.4	1.08	0.91
			P	Average	18.99	16.63		1.34	1.23
	_						_		
PFE	Pfizer Inc.	\$25.06	\$ 1.40	\$ 1.37	17.93	18.29	2.5	7.23	7.38

Implied Relative Value:

P/E (EPS25)	\$ 26.54
P/E (EPS26)	\$ 22.78
PEG (EPS25)	\$ 4.65
PEG (EPS26)	\$ 4.17

Pfizer Inc. *Key Management Ratios*

Fiscal Years Ending Dec. 31	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Liquidity Ratios:													
Current Ratio (Current Assets /Current Liabilities)	1.22	0.91	1.17	1.16	1.37	1.57	1.77	2.00	2.25	2.51	2.79	3.09	3.41
Quick Ratio (Cash & Cash Equivalents + Net Accounts Rece	0.80	0.51	0.74	0.79	0.99	1.20	1.40	1.64	1.89	2.15	2.43	2.74	3.06
Cash Ratio (Cash & Cash Equivalents / Current Liabilities)	0.01	0.06	0.02	-0.10	0.05	0.27	0.47	0.71	0.95	1.22	1.50	1.80	2.12
Asset-Management Ratios:													
Total Asset Turnover Ratio = Revenue / Average Total Asse	0.51	0.26	0.30	0.33	0.32	0.33	0.33	0.33	0.33	0.32	0.32	0.31	0.30
Receivable Turnover Ratio = Revenue / Average Net Receiv	8.91	5.17	5.84	6.43	6.12	6.12	6.14	6.16	6.16	6.16	6.16	6.16	12.58
Average Days Sales in Receivables = 365 / Receivable Turn	40.96	70.57	62.50	56.77	59.61	59.63	59.47	59.26	59.26	59.30	59.25	59.28	29.02
Financial Leverage Ratios:													
Debt to Equity Ratio = Total Liabilities / Total Stockholder I	1.06	1.54	1.41	1.11	1.03	0.99	0.94	0.88	0.83	0.78	0.72	0.67	0.63
Shareholder Equity Ratio = Total Shareholder Equity / Tota	0.49	0.39	0.41	0.47	0.49	0.50	0.51	0.53	0.54	0.56	0.58	0.59	0.61
Financial Leverage = Total Debt / Shareholder Equity	0.34	0.69	0.65	0.58	0.55	0.51	0.48	0.45	0.42	0.38	0.35	0.33	0.30
Profitability Ratios:													
Return on Equity Ratio (ROE) = (NI/Beg TSE)	40.63%	2.22%	9.02%	8.82%	8.01%	9.62%	10.78%	11.99%	11.41%	11.56%	11.63%	11.59%	11.60%
Return on Assets Ratio (ROA) = Net Income / Average Tota	14.82%	0.98%	3.96%	4.01%	3.74%	4.48%	5.04%	5.70%	5.57%	5.77%	5.94%	6.08%	12.91%
Quality of Income (Earnings Quality) = Cash flows from op	93.19%	403.15%	158.07%	127.87%	209.11%	190.17%	172.78%	153.82%	161.62%	156.76%	152.04%	147.81%	143.91%
Payout Policy Ratios:													
Dividend Payout Ratio (Dividend/EPS)	28.65%	435.81%	118.33%	123.05%	128.49%	101.78%	84.70%	69.88%	66.28%	58.99%	52.49%	46.84%	41.43%
Total Payout Ratio ((Divs. + Repurchases)/NI)	34.97%	428.50%	117.99%	123.18%	128.63%	101.89%	84.79%	69.96%	66.35%	59.06%	52.56%	46.90%	41.49%
Retention Ratio = (NI - Dividends)/NI	71.40%	-328.50%	-17.99%	-23.05%	-28.49%	-1.78%	15.30%	30.12%	33.72%	41.01%	47.51%	53.16%	58.57%

Valuation of Options Granted under ESOP

Current Stock Price	\$25.06
Risk Free Rate	4.32%
Current Dividend Yield	6.06%
Annualized St. Dev. of Stock Returns	23.96%

(in millions)

Range of	Number	Average Exercise	Average Remaining	B-S Option	Value of Options
Outstanding Options	of Shares	Price	Life (yrs)	Price	Granted
Range 1	19.62	33.24	1.90 \$	2.25 \$	44.15
Range 2				\$	-
Total	19.62 \$	33.24	1.90 \$	1.36 \$	44.15

Effects of ESOP Exercise and Share Repurchases on Common Stock Account and Number of Shares Outstanding

Number of Options Outstanding (shares): 19.62 millions

Average Time to Maturity (years): 1.90 Expected Annual Number of Options Exercised: 10.33

Current Average Strike Price:\$ 33.24Cost of Equity:6.63%Current Stock Price:\$25.06

Millions of Dollars

Willions of Dollars											
Fiscal Years Ending Dec. 31		2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Increase in Shares Outstanding:		10	10	10	10	10	10	10	10	10	10
Average Strike Price:	\$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24 \$	33.24
Increase in Common Stock Account:		343	343	343	343	343	343	343	343	343	343
Share Repurchases (\$)		5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290
Expected Price of Repurchased Shares:	\$	25.06 \$	25.20 \$	25.34 \$	25.49 \$	25.63 \$	25.78 \$	25.92 \$	26.07 \$	26.22 \$	26.37
Number of Shares Repurchased:	'	211	210	209	208	206	205	204	203	202	201
Shares Outstanding (beginning of the year)		5,664	5,463	5,264	5,065	4,868	4,672	4,477	4,283	4,091	3,899
Plus: Shares Issued Through ESOP		10	10	10	10	10	10	10	10	10	10
Less: Shares Repurchased in Treasury		211	210	209	208	206	205	204	203	202	201
Shares Outstanding (end of the year)		5,463	5,264	5,065	4,868	4,672	4,477	4,283	4,091	3,899	3,709

Effective Tax Rate

Sensitivity Tables

					Beta			
	23.08	0.12	0.22	0.32	0.42	0.52	0.62	0.72
	6.48%	59.26	35.99	25.51	19.54	15.67	12.96	10.95
Premium	6.23%	61.05	37.27	26.49	20.33	16.33	13.53	11.45
Ē	5.98%	62.96	38.63	27.53	21.17	17.05	14.15	12.00
Pre	5.73%	64.98	40.08	28.66	22.09	17.82	14.82	12.59
Risk	5.48%	67.13	41.65	29.87	23.08	18.65	15.54	13.22
	5.23%	69.43	43.33	31.18	24.15	19.56	16.32	13.92
Equity	4.98%	71.88	45.15	32.60	25.31	20.54	17.18	14.67
Eq	4.73%	74.51	47.12	34.16	26.59	21.63	18.12	15.50
	4.48%	77.33	49.26	35.85	27.99	22.81	19.15	16.41

				Ri	sk Free Ra	te		
	23.08	2.82%	3.32%	3.82%	4.32%	4.82%	5.32%	5.82%
ebt	7.71%	44.60	32.25	25.06	20.34	17.01	14.53	12.61
ťΩ	6.71%	48.34	34.24	26.29	21.19	17.63	15.00	12.98
Cost of Debt	5.71%	52.73	36.47	27.65	22.10	18.28	15.49	13.37
Š	4.71%	57.94	39.00	29.13	23.08	18.98	16.01	13.77
ах	3.71%	64.24	41.86	30.77	24.14	19.72	16.57	14.20
Pre-Tax	2.71%	72.00	45.16	32.59	25.29	20.52	17.15	14.64
P	1.71%	81.80	48.97	34.61	26.54	21.37	17.77	15.12

			COG	S as % of	Sales		
23.08	18.59%	19.59%	20.59%	21.59%	22.59%	23.59%	24.59%
40.0%	18.86	18.10	17.33	16.57	15.80	15.04	14.27
35.0%	20.66	19.82	18.98	18.15	17.31	16.47	15.63
30.0%	22.50	21.58	20.67	19.76	18.84	17.93	17.01
25.0%	24.37	23.38	22.39	21.40	20.41	19.42	18.43
20.0%	26.29	25.22	24.15	23.08	22.01	20.94	19.87
15.0%	28.24	27.09	25.94	24.79	23.64	22.49	21.34
10.0%	30.24	29.00	27.77	26.54	25.30	24.07	22.83

			Co	ost of Equi	ty		
23.08	3.6%	4.6%	5.6%	6.6%	8.6%	10.6%	12.6%
10.1%	21.64	21.84	22.05	22.26	22.67	23.08	23.48
9.1%	21.84	22.05	22.26	22.46	22.87	23.28	23.69
8.1%	22.05	22.26	22.46	22.67	23.08	23.48	23.89
7.1%	22.26	22.46	22.67	22.87	23.28	23.69	24.09
6.1%	22.46	22.67	22.87	23.08	23.48	23.89	24.30
5.1%	22.67	22.87	23.08	23.28	23.69	24.09	24.50
4.1%	22.87	23.08	23.28	23.48	23.89	24.30	24.70
3.1%	23.08	23.28	23.48	23.69	24.09	24.50	24.90
2.1%	23.28	23.48	23.69	23.89	24.30	24.70	25.10

Current Dividend Yield

WACC

1-Year Sales Decline

	SGA as % of Sales								
23.08	19%	21%	23%	25%	27%	29%	31%		
7.8%	16.73	15.43	14.13	12.83	11.54	10.24	8.94		
7.3%	19.70	18.20	16.71	15.21	13.72	12.22	10.73		
6.8%	23.73	21.97	20.20	18.44	16.68	14.92	13.16		
6.3%	29.52	27.37	25.23	23.08	20.94	18.80	16.65		
5.8%	38.55	35.81	33.07	30.32	27.58	24.84	22.10		
5.3%	54.63	50.82	47.02	43.21	39.40	35.59	31.78		
4.8%	91.31	85.07	78.82	72.58	66.34	60.10	53.86		

			CV Gr	owth of NC	PLAT		
23.08	2.50%	3.00%	3.50%	4.00%	4.50%	5.00%	5.50%
-62.50%	14.59	16.67	19.50	23.58	29.94	41.25	67.01
-67.50%	14.49	16.56	19.38	23.43	29.76	41.02	66.64
-72.50%	14.39	16.45	19.26	23.29	29.58	40.78	66.27
-77.50%	14.29	16.35	19.13	23.15	29.41	40.55	65.91
-80.00%	14.25	16.29	19.07	23.08	29.32	40.44	65.73
-82.50%	14.20	16.24	19.01	23.01	29.24	40.32	65.55
-87.50%	14.10	16.13	18.90	22.87	29.07	40.10	65.20
-92.50%	14.01	16.03	18.78	22.73	28.90	39.88	64.85
-97.50%	13.92	15.93	18.66	22.59	28.73	39.65	64.51

	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Amortization Expense Schedule (from 10K nc	5,286	4,838	4,716	4,125	3,776	2,829					
LT Debt Maturity Schedule (from 10K notes)	0	0	6000	980	5660	1750	5250	1350	1350	1350	1350
LI Debt Maturity Scredule (ITOH) Tok Hotes)	U	U	0000	360	3000	1/30	3230	1330	1330	1330	1330
Management CapEx Guidance (forecasting)	-2,750	-3,268	-3,050	-3,098	-3,217	-3,200	-3,251	-3,304	-3,333	-3,378	-3,422
Share Repurchases (\$, if applicable)	0	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290	5,290
Total Dividends Paid											
Beginning of FY Shares Outstanding	5,657_	5,565	5,363	5,164	4,967	4,770	4,575	4,380	4,187	3,995	3,804
Expected Dividend per Share	\$ 1.68 \$	1.72 \$	1.76 \$	1.80 \$	1.84 \$	1.88	\$ 1.92 \$	1.96 \$	2.00	\$ 2.04 \$	2.08
Total Dividends Paid (\$)	-9,512	9,572	9,440	9,296	9,139	8,968	8,783	8,585	8,374	8,150	7,913
The area below is for calculating HISTORICAL m	patrics to rafa	rancad whan	huilding for	ecasts.							
The direct below is joi ediculating mistorical m	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
epreciation Rate:											
Depreciation Expense	1498	1429	1701	1511	1491	1400	1333	1491	5064	6290	7013
Beginning Net PPE		11,762	13,766	13,318	13,865	13,385	12,969	13,900	14,882	16,274	18,940
Implied Depreciation Rate (%)		12.15%	12.36%	11.35%	10.75%	10.46%	10.28%	10.73%	34.03%	38.65%	37.03%
Marginal Tax Rate (%)											
US Statutory (Federal) Tax (%)	9%	4%	-1%	-6%	-8%	-4%	-11%	-2%	-2%	-121%	-18%
Current Federal Tax	393	67	342	1,267	668	(1,887)	372	3,342	2,744	1,321	453
Deferred Federal Tax	725	300	(419)	(2,064)	(1,663)	1,254	(1,164)	(3,850)	(3,271)	(2,606)	(1,909)
State and Local Tax (%)	-1%	0%	-2%	-2%	0%	1%	-1%	-2%	-1%	-30%	-3%
Current SALT	85	(8)	(52)	45	9	(186)	56	34	(20)	(135)	32
Deferred SALT	(256)	(36)	(106)	(304)	16	276	(131)	(491)	(310)	(184)	(293)
Foreign Income Tax (%)	18%	19%	16%	22%	19%	8%	18%	12%	12%	46%	21%
Current International Tax	2,321	1,951	1,532	2,709	2,831	2,418	1,517	2,769	4,368	1,142	1,588
Deferred International Tax	(149)	(284)	(175)	(42)	(558)	(969)	(279)	48	(183)	, (652)	100
Implied Marginal Tax Rate	25.48%	22.20%	13.44%	13.09%	10.96%	5.12%	5.27%	7.62%	9.58%	-105.29%	-0.36%
Iormal Cash Calculation (%)											
Cash from B/S	3,343	3,641	2,595	1,342	1,139	1,121	1,784	1,944	416	2,853	1,043
Revenue	49,605	48,851	52,824	52,546	53,647	51,750	41,651	81,288	101,175	59,554	63,627
Cash as a % of Sales	6.74%	7.45%	4.91%	2.55%	2.12%	2.17%	4.28%	2.39%	0.41%	4.79%	1.64%
ividend Payout Ratio (%)											
Total Dividends	6,609	6,940	7,317	7,659	7,978	8,043	8,440	8,729	8,983	9,247	9,512
Net Income	9,136	6,959	7,214	21,310	11,153	16,273	9,160	21,980	31,370	2,119	8,031
Implied Payout Ratio (%)	72.34%	99.73%	101.43%	35.94%	71.53%	49.43%	92.14%	39.71%	28.64%	436.39%	118.44%
verage % tax payable -		21.01%	38.91%	-5.27%	-475.56%	168.10%	283.51%	68.36%	47.69%	-210.67% -	
Dividend per share	1.04	1.12	1.2	1.28	1.36	1.44	1.52	1.56	1.6	1.64	1.68 <u>S</u>
Annual dividend increase		0.08	0.08	0.08	0.08	0.08	0.08	0.04	0.04	0.04	0.04
		0.00	0.00	0.00	5.50	0.00	0.00	0.04	5.0∓	0.0 т	5.04